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The thesis attempts to examine some of the biochemical 
interactions between natriuretic peptides and cultured mouse astrocytes. 
A single class of receptor for natriuretic peptides are found in 
astrocytes with a dissociation constant (K^ of 0.2-0.3nM and maximal 
binding capacity (Bmax) between 42 to 90 finol/mg using iodinated 
peptides. Displacements of different radiolabelled ligands by various 
natriuretic peptides reveal a close range of half-maximal inhibitory 
concentrations ( I C 5 0 ) from 0.1 to 0.4nM. Binding to this receptor will 
generate cGMP production in a time- and dose-dependent maimer. The 
half-maximal stimulatory concentrations ( E C 5 0 ) for both hANP and 
pBNP are approximately lOOnM although pBNP exhibits greater 
maximal stimulation. Binding of natriuretic peptides to mouse astrocytes 
and cGMP production in response to them are not affected by acute 
treatment of angiotensin II. The similarity of binding characteristics of 
a-hANP and pBNP, and the fact that no additive or synergistic but 
inhibitory effect is observed when both peptides are studied together 
suggest that ANP and BNP bind to a common receptor and employ the 
same effector system to generate cGMP. 
Natriuretic peptides do not affect basal cAMP production 
although they can inhibit cAMP production in response to low 
concentrations of forskolin. 
With respect to biological actions. Natriuretic peptides inhibit 
thymidine incorporation in a dose-dependent manner. The second 
Page V 
Abstract 
messenger mediating this action is not identified yet but it seems not to 
involve cGMP. However, they have no action on potassium transport 
and taurine release in mouse astrocytes. 
Finally, interactions between astrocytes and natriuretic peptides 
are affected by culture conditions. Undifferentiated mouse astrocytes 
show a decreased cGMP production in response to pBNP and acute 
treatment of forskolin in these cells can induce an increase in binding 
sites for natriuretic peptides. 
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4. GENERAL INTRODUCTION 
Atrial natriuretic peptide (ANP)l was first identified in 1981 by 
de Bold et al. (1981). They demonstrated that bolus injection of cardiac 
atrial extracts caused a profound natriuresis and lowering of atrial 
pressure. In a search for the factor responsible, 3 research teams 
reported independently the presence of a peptide hormone containing 
28 amino acids, together with its complete sequence (Currie et al., 
1984; Flynn et al., 1983; Kangawa and Matsuo, 1984). Since the 
discovery of this atrial natriuretic peptide (ANP), it has been the subject 
of much research (see review by Baxter, 1988), and a number of 
synthetic analogues have been developed to assist with this (Nutt and 
Veber，1987; Olins et al” 1988). 
Subsequently, other structurally and functionally related peptides 
have been identified. Brain natriuretic peptide (BNP), first isolated, 
identified and sequenced in porcine brain by Sudoh et al. (1988), is a 26 
amino acid peptide sharing both structural and functional similarity to 
ANP. More recently, a C-type natriuretic peptide (so designated 
following ANP and BNP) was also discovered by Sudoh et al. (1990)， 
also in porcine brain. Both of these peptides also elicit vasorelaxant, 
natriuretic and diuretic responses in a manner similar to ANP (Sudoh et 
al., 1990). These peptides all share a common structural motif of a 17-
1 The hormone has been assigned a variety of names in the literature - e.g. atriopeptin, 
cardioatrin, aunculin. Although an international committee has recommended the generic 
term 'atrial natriuretic factor (ANF)' (Dzau et al., 1987), there is a trend in the more recent 
literature to prefer the term ’atrial natriuretic peptides'. The author is also more inclined to the 
term atrial natriuretic peptide due to the protein nature of the hormone. 
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amino acid loop formed by an intramolecular disulfide linkage (Furuya 
et al.，1992) which is believed to be essential for binding to functional 
receptors on target cells (see fig. 5.3.3) 
Natriuretic peptides exhibit actions that tend to oppose those of 
agents that increase blood pressure or extracellular volume. They 
promote a decrease in blood pressure in association with 
vasorelaxation, an increase in glomerular filtration rate (GFR) with 
enhanced sodium ion and water excretion by the kidney, and an 
inhibition of the release and actions of various pressor and water-
retaining hormones such as angiotensin and vasopressin (see review by 
Baxter, 1988). 
ANP acts via specific receptors on the surface membrane of target 
cells (see review by Waldman and Murad, 1989). The binding 
characteristics and distribution of ANP receptors have been studied by 
examining the binding of radio-iodinated ANP to whole cell and 
membrane preparations derived from various tissues under direct 
equilibrium binding conditions, and by receptor autoradiographic 
techniques (Leitman and Murad, 1987; Delean et al., 1984; Inui et al., 
1985; Napier et al.，1984). Specific ANP receptors have been identified 
in tissues where the peptide elicits biological responses, including 
vascular endothelial, and vascular smooth muscle cells, epithelial and 
mesangial cells of the renal glomerulus, renal papilla, adrenal, and 
various regions in the central nervous system (DeLean et al.，1984; Inui 
et al., 1985; Napier et al.，1984; Shenk et al., 1985; Zamir et al, 1986). 
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Many hormones originally isolated in peripheral tissues such as 
the gastrointestinal tract, have been demonstrated also to have receptors 
and to be synthesized in and secreted by the brain. Thus, it is not 
surprising that natriuretic peptide receptors have been detected in the 
central nervous system (CNS). Natriuretic peptide receptors are widely 
distributed within the central nervous system (see review by Samson 
1987). 
In the brain, more than half of the volume does not consist of 
excitable cells. The largest class of non-excitable cells are the neuroglia 
of which the most numerous are the astrocytes. Named for their stellate 
shape，astrocytes were identified in the 19th century (Virchow, 1846). It 
has been assumed previously that they serve as little more then passive 
physical support elements for neurons. However, recent advances have 
shown that astrocytes have key roles in normal brain physiology, in 
brain development and in the pathology of the nervous system. The 
normal functioning of neurons depends to a very large extent on the 
normal functioning of surrounding astrocytes (Kimelberg and 
Norenberg, 1989). Astrocytes are now known to be metabolically 
highly active, complex cells which are important in maintaining a stable 
ionic environment and are the main site for neurotransmitter amino acid 
metabolism in the CNS. 
The complexity of neuronal responses in the CNS is thought to 
result, in large part, from interactions between neurohormones and 
transmitters on receptors. Many receptors and second messenger 
Page 3 
Chapter 4: General Tntrndurtinn 
systems first found in neurons have now been identified also in • 
astroglial cells. 
Recently, ANP immunoreactivity and specific ANP binding has 
been demonstrated in both neuronal and glial cells of rat brain 
indicating that specific receptors are present in both cell types (Friedl et 
al.，1987). To investigate this further, cultured neurons and glial cells 
have been used (Sumner and Tang, 1992). I^Sj.aNP binding has been 
observed in both cell types and is associated with intracellular cGMP 
accumulation in response to ANP. Most hypotheses have focused on 
ANP actions upon neurons and their relation to central volume 
regulation. For example, ANP decreases neuronal excitability in the 
septum, preoptic area (Wong et al., 1986) and parvocellular neurons in 
the paraventricular nuclei of AV3V neurons (Okuya and Yamashita, 
1987). Intracerebroventricular administration of ANP inhibits water 
intake induced by angiotensin II (Nakamura et al.，1985)，vasopressin 
release (Samson et al., 1987)，and inhibits the increase in blood pressure 
in spontaneously hypertensive rats (Levins et al” 1989) and potentiates 
the central depressor effect of saralasin (Shimizu et al.，1986). 
However, the interaction of natriuretic peptides with glial cells such as 
astrocytes, has received less attention and has not, to date, demonstrated 
any clear physiological role. 
This thesis was primarily designed to evaluate the biochemical 
aspects of the interaction between natriuretic peptides and astrocytes, 
and to investigate the possible actions of the hormones in these cells. 
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5. REVIEW OF LITERATURE 
5.1 Historical Background of Natriuretic Peptides 
It has been known for some time that homeostatic mechanisms 
exist to counter the actions of factors that increase fluid volume and 
blood pressure. In the early 1950s, it was hypothesized by de Wardner 
that there must be a humoral factor, sensitive to blood pressure and 
intravascular volume, which regulated the excretion of sodium and 
water to maintain fluid, electrolyte and hemodynamic homeostasis (De 
Wardner et al.，1961). Speculation that tbe heart is a secretory organ can 
be attributed to Kisch who，in 1956, found that it contains secretory 
granules (Kisch, 1956). Later, dense granules were observed in atrial 
cardiocytes (Jamieson and Palade, 1964). These atrial granules have 
characteristics similar to secretory granules in other tissues that are 
responsible for hormone production and secretion and early evidence 
implicated these granules in processes related to electrolyte balance and 
fluid volume homeostasis. For example, the number of granules can be 
increased by sodium restriction and decreased by sodium loading 
(DeBold 1979). 
However, it was not until 1981 that the responsible factor was 
identified. In this year, deBold et al. (1981) demonstrated that rat atrial 
extracts contain a factor that stimulates natriuresis and diuresis. During 
an intensive effort to characterize this factor, a family of peptides of 
different lengths (21 to 33 amino acids) were isolated from animal and 
human atrial tissue and these peptides had in common a 17 amino acid 
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ring formed by a disulfide link between two cysteine residues (Currie et ‘ 
al.，1984; Flynn et al.，1983; Kangawa and Matsuo, 1984). 
Subsequently, these peptides were purified, characterized and 
sequenced (Currie et al, 1984; Flynn et al.，1983; Kangawa and 
Matsuo, 1984). This family contains low-molecular weight, heat stable 
peptides which are collectively termed atrial natriuretic peptides 
(ANPs). Three distinct components of different molecular weights 
(MW - 3000 for a , 6000 for 6，and 13000 for y) were shown in HPLC 
profiles in human plasma (Kangawa et al., 1985). Kanagawa and 
Matsuo (1985) later identified a-hANP as a 28 amino acid peptide and 
the 6000 dalton peptide (6-hANP) as an anti-parallel dimer of a-hANP 
and the y-form as a 126 amino acid peptide which carries the a-hANP 
sequence at its carboxyl terminus (Kangawa et al.，1985). It has now 
been established that the major active form of ANP released into and 
circulating in human plasma is a 28 amino acid a-hANP (Miyata et-al•， 
1987). 
The existence of these peptides explains the mineralocorticoid 
'escape' phenomenon where by administration of deoxycorticosterone 
results in progressive sodium retention to a certain level, after which no 
further retention occurs in spite of continued administration of the 
hormone (Metzler et al.，1987). It is believed that ANPs are released in 
response to atrial stretch resulting from increased blood pressure or 
fluid volume expansion and then act to promote compensatory 
vasodilation and diuresis. 
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Since the discovery of the ANPs, a second natriuretic peptide, 
originally isolated from porcine brain (Sudoh et al.，1988) and thereafter > 
named brain natriuretic peptide (BNP), was discovered. It was later 
found to be secreted from the ventricles and to a lesser extent atria of the 
heart (Minamino et al., 1988). It elicits actions very similar to ANP (Itoh 
et al., 1988). Recently, a third member of the natriuretic peptide family 
designated as C-type natriuretic peptide (CNP) has been identified in 
porcine brain (Sudoh et al., 1990). BNP is a 26 amino acid peptide while 
CNP has 22 amino acid residues. Both show close sequence homology 
to ANP with retention of the ring structure produced by an 
intramolecular disulfide bond between two cysteine residues at the 
position 7 from the carboxyl terminus (Sudoh et al., 1990) (fig. 5.3.3). 
However, CNP is found principally in the CNS. CNP-like 
immunoreactivity is present in the hypothalamus at a relatively high 
concentration (Komatsu et al., 1991). It is also found in cerebellum in 
contrast to ANP and BNP (Morii et al., 1985; Ogawa et al, 1990). In 
addition, CNP mRNA is hardly detectable in cardiac tissues (Sudoh et 
al., 1990) in contrast to observations that the heart is the major source of 
ANP and BNP (Ogawa et al., 1990; Nakao et al., 1984). These findings 
suggest that CNP works mainly as a neuropeptide, while ANP and BNP 
act mainly as cardiac hormones and raise the possibility that the 
physiological functions of these peptides may occur through a dual 
mechanism involving both central neuronal and peripheral control. 
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5 � Secretion of natriuretic peptides ‘ 
The major circulating form of ANP in the human and the rat is a 
28-ammo acid peptide which results from cleavage of pro-ANP at the 
carboxyl terminal side of a serine residue (Schwartz et al., 1985) (see 
fig. 5.3.1). The cleavage is catalyzed by an enzyme located on the cell 
membrane of atrial cardiocytes which converts pro-ANP to ANP^pp. 
126) by cleaving the Arg-Ser bond during the exocytotic secretion of 
pro-ANP from its storage vesicles (Imada et al.，1988). Involvement of 
protein kinase C has been suggested since simultaneous administration 
of both phorbol ester and forskolin can stimulate ANP release (Lang et 
al, 1985). 
In addition to atrial cardiocytes, ANP is synthesized and stored in 
a number of other tissues. ANP gene expression has been observed in 
aortic arch (Gardner et al.，1987), lung (Gardner et al.，1986), anterior 
pituitary (Gardner et al.，1986), hypothalamus (Gardner et al., 1986), 
adrenals (Ong et al.，1987) and kidney (Sakamoto et al., 1985). Within 
the heart, ANP gene is expressed in both ventricles and atria. The 
concentration in ventricles is higher than in atria in foetal animals while 
the ratio reverses in adult animals (Bloch et al.，1986). The contribution 
of each to the overall output and actions of circulating ANP remain 
uncertain. 
Secretion and release is controlled by a number of factors 
including acute (Lang et al” 1985) and chronic (Metzler et al” 1987) 
volume expansion, and congestive cardiac failure (Ding et al.，1987). 
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The most important and well documented stimulus is probably atrial • 
stretch (Dietz, 1984). Using an isolated rat heart-lung preparation, Dietz 
(1984) demonstrated the presence of a natriuretic substance in 
perfusate, arising in response to an increase in right atrial pressure. This 
was subsequently confirmed to be ANP by specific radioimmunoassay 
(Dietz, 1984). It was further demonstrated that ANP can be released 
into the circulation in vivo following volume expansion (Cantin et al” 
1984). 
Ruskoaho et al. (1986) demonstrated that ANP release occurs as a 
result of direct stretch of the atrial wall. They found a rise in 
immunoreactive ANP in the perfusate collected from the isolated 
perfused Langendorff heart preparation (which has no extrinsic neural 
connections) as the right atrial pressure was raised by 1-5 mmHg. 
Results of both intact animal experiments and in vitro studies leave no 
doubt that atrial stretch is a potent stimulator of ANP release. Evidence 
in man also supports the role of atrial stretch. Saline infusion (Tunny et 
al., 1986) and exercise (Bollerslev et al., 1987) both of which increase 
atrial pressure (i.e. atrial stretch) are accompanied by a rise in plasma 
ANP. It now seems clear that any manoeuvre conducive to a direct 
stretch of the atrial wall stimulates ANP release. However, it is still not 
clear which intracellular signalling system mediates this response. 
In addition to atrial stretch, other factors play a role in the control 
of release of ANP. These include hormonal and neural elements. For 
example, intravenous administration of vasopressin to anaesthetized 
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dogs elicits an increase in plasma ANP (Inoue et al.，1988). Also, • 
noradrenaline produces a biphasic rise in ANP secretion by both a- and 
6-adrenergic mechanisms from isolated rat atria (Schieginger et al.， 
1987). Furthermore, intracerebroventricular administration of 
angiotensin II significantly enhances ANP secretion induced by volume 
loading with saline in rats (Itoh et al., 1988). In addition to hormonal 
control, activation of the sympathetic nervous system tends to enhance 
ANP secretion, whereas a rise in parasympathetic tone? may lower ANP 
secretion. 
Long term control of ANP secretion involves control of ANP 
gene expression. This is known to be regulated by several hormonal and 
non-hormonal factors which affect the cardiovascular system. 
Glucocorticoid hormones can stimulate ANP gene expression (Gardner 
et al., 1986). The second intron of the human ANP gene contains the 
sequence TCTATTGTCCT, which has moderate homology with.the 
glucocorticoid-regulatory element that mediates glucocorticoid receptor 
function (Karin et al.， 1984). In addition, results of the 
mineralocorticoid escape experiments, mentioned above, show that 
plasma ANP concentrations increase in a time frame that coincides with 
the 'escape' from the mineralocorticoid effect, and that this is followed 
by enhanced synthesis of pro-ANP with increased atrial ANP mRNA 
concentrations (Ballerman et al.，1986; Zimmerman et al” 1987). 
Thyroid hormones can also regulate ANP gene expression. 
Administration of thyroxine (T4) to dehydrated rats increases atrial 
Page 10 
Chavter 5: Review of UtRrnp广〒 
ANP mRNA concentrations by approximately three-fold and plasma • 
ANP concentrations by approximately two-fold (Gardner et al” 1987). 
Non-hormonal factors also influence ANP gene expression. For 
example, prolonged dehydration can result in a substantial reduction in 
the amount of ANP mRNA in atria (Takayanagi et al.，1985). Chronic 
alterations in dietary sodium have also been shown to result in small but 
significant changes in ANP mRNA level (Takayanagi et al., 1985). 
Thus, control of ANP secretion is a complex process influenced 
by many factors. 
BNP, on the other hand, is predominantly secreted from the 
ventricle in humans. In one study, human plasma BNP-like 
immunoreactivity in the coronary sinus was shown to be 2-3 times 
higher than in the aortic root, indicating that BNP is secreted into the 
circulation via the coronary sinus (Nakao et al., 1990). It also 
demonstrated that 70% of the total BNP mRNA content of the heart was 
contained in the ventricle. The result is consistent with observations in 
rat heart which show that approximately 60% of secreted rat BNP is 
derived from the ventricle (Ogawa et al., 1990). Results, using human 
subjects with congestive cardiac failure (Nakao et al.，1990), indicate 
that regulation ofhBNP secretion differs from that of ANP and raise the 
possibility that BNP may be more important than ANP in pathological 
states such as congestive cardiac failure. 
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53. Structure and Function Relationships 
ANP is produced as prepro-ANP, a peptide containing 149-153 
amino acids (Seidman et al.，1984) depending on species (151 amino 
acids in humans). Prepro-ANP contains a signal peptide at its amino 
terminus. Upon cleavage of this signal sequence, a 126 amino acid 
peptide pro-ANP，is generated (Lewicki et al” 1986). Pro-ANP is 
subsequently cleaved further to produce a 28 amino acid biologically 
active hormone during the secretory process (Thibault et al., 1985) (fig. 
5.3.1). 
The amino acid sequence of circulating ANP is almost identical 
throughout mammalian species with the exception of the amino acid in 
position 110. This residue is isoleucine in the mouse, rat (Flynn et al.， 
1983) and rabbit, and methionine in humans (Kangawa and Matsuo, 
1984) and dogs (fig. 5.3.2). ANPs of different species all show an 
intramolecular disulfide bond between cystine residues at positions 7 
and 23 from the carboxyl terminus which produces a ring structure 
composed of 17 amino acids (Kangawa and Matsuo, 1984). Reduction 
and alkylation of the cystine disulfide bond abolishes activity, 
indicating that the cyclic ring is essential for function. This is further 
supported by the fact that synthetic peptides achieve maximal biologic 
activity only when they have been oxidized to form the cystine 
disulfide link. 
In 1988, a ftuther natriuretic peptide with 26 amino acid residues 
was identified and sequenced in porcine brain (Sudoh et al., 1988). It 
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was termed brain natriuretic peptides (BNP). It was later found to be • 
present in the heart (Minamino et al., 1988). The amino acid sequence 
of BNP is similar to but distinct from ANP. The physiological effects of 
BNP are very similar to those of ANP. However, the molecular form of 
BNP shows more divergence between species (fig. 5.32). Porcine BNP 
(PBNP) is a 26-ammo acid peptide (Sudoh et al.，1988); whereas, 
human BNP (hBNP) is a 32-amino acid peptide and rat BNP (rBNP) 
contains 45 amino acid residues (Suga et al.，1992). 
Recently, a third member of the natriuretic peptide family, C-type 
natriuretic peptide (CNP), has been isolated from porcine brain (Sudoh 
et al., 1990). It was first isolated as a 22-amino acid peptide (see fig. 
5.3.2 for sequence) but a 53 amino acid peptide (CNP-53) is now 
known to be the endogenous molecular form in porcine brain (Kojima 
et al., 1990). Subsequent nucleotide sequence analysis of the CNP 
precursors shows that the amino acid sequence of human (hCNP),- rat 
(rCNP) and porcine (pCNP) are identical (Ogawa et al” 1991; Tawaragi 
et al., 1991)，indicating that the structure of marmnalian CNP has been 
highly conserved during evolution. CNP also contains the ring 
structure, formed by an intramolecular disulfide bond, as in ANP and 
BNP. However, unlike ANP and BNP, the C-terminal extension from 
the ring is missing (see fig. 5.3.3). Expression of the CNP gene is 
confined to brain only (Kojima et al” 1990) suggesting that it acts 
mainly as a neuropeptide. 
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Fig. 53.1 ANP gene structure and expression, processing of pro-ANP and 
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Fig. 5.3.2 Amino acid sequences of natriuretic peptides family and sequence 


































Fig. 5.3.3 (a) Amino acid sequences and structures of a-ANP, BNP-32 and 
porcine CNP. Intramolecular disulfide linkage is formed between two cysteine 
residues in each peptide. Identical residues among three peptides are shaded, 
(b) Schematic representation of porcine a-ANP, BNP-32 and CNP structures. 
Identical residues among three peptides are indicated by open circles. 
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5.4. Physiological Actions of Natriuretic Peptides 
The following review will concentrate on ANP and BNP as they • 
bave been more thoroughly investigated. The actions of CNP2 in 
peripheral tissues are broadly similar to those of ANP but with lower 
potency. 
ANP elicits a variety of responses which are all directed towards 
the reduction of blood pressure and blood volume. 
1. Cardiovascular actions 
DeBold et al. (1981) first reported that atrial extracts from rat 
atrium caused a fall in blood pressure together with diuresis and 
natriuresis. This hypotensive effect has been confirmed by 
administration of synthetic ANP into animals and man (Kangawa and 
Matsuo, 1984). It is believed that the hypotensive action of ANP is in 
part due to a vasorelaxant action on arterial smooth muscle. However, it 
has also been hypothesized that the hypotensive action is predominantly 
due to a decrease in cardiac output (Cody et al., 1986; Saito et al., 1987) 
mediated mainly by two mechanisms. Firstly, ANP may exert 
vasorelaxant effects on the venous system, thereby reducing preload 
(Saito et al.，1987). Secondly, it promotes a fluid egress from the 
circulation (Huxley et al., 1986). The potent vasorelaxant effect of 
2 The pharmacological effects of CNP are very similar to a-hANP (Sudoh et al. 1990). 
However, in some tissues e.g. smooth muscle cells (Funiya et ai 1990) and astrocytes (Yeimg 
et al 1992), CNP increases the level of cGMP with much greater potency. The significance of 
this is still under investigation. 
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ANP on smooth muscle has been confirmed in vitro (Leitman and • 
Murad, 1987). The actions are more prominent when a high degree of 
vasoconstrictor activity is present. For example, ANP can antagonize 
angiotensin II induced vasoconstriction (Winquist 1987). The overall 
profile of ANP-induced vasorelaxation is similar to that of certain other 
vasodilators such as sodium nitroprusside, consistent with the finding 
that both classes of drugs activate guanylate cyclase (Samson 1985). 
BNP also has potent hypotensive effects similar to those of ANP. 
Intravenous injection of BNP produces a rapid and marked natriuresis 
and hypotension in DOCA-salt loaded rats (Kita et al.，1989). However, 
the hypotensive effect of BNP is less than that of a-hANP in 
spontaneously hypertensive rats. The mechanism involved is believed 
to be similar with both peptides as BNP binding sites are found in 
endothelial cells，smooth muscle cells and fibroblasts. BNP also 
increases intracellular cyclic GMP in a maimer similar to ANP (Song et 
al, 1988). 
II. Renal actions 
The earliest known effects of ANP were diuresis and natriuresis. 
Atrial extracts from different mammalian species such as rat, mouse, 
hamster, dog and pig, consistently showed such effects (deBold et al. 
1981; Forssmann et al. 1983; Nemeh and Gimore 1983). It is now 
known that ANP stimulates an increase in glomerular filtration rate 
(GFR) and renal excretion of water as well as sodium, chloride, 
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magnesium, calcium and phosphate ions (Ballerman and Brenner, 1985; • 
Atlas 1986). The diuretic potency of ANP is over 1000-fold greater 
than that of fiirosemide but the action is rapid (within 5 mins) and 
relatively short-lived (20-30 mins) (Cogan, 1986; Huang et al” 1985). 
The increased GFR may be due to increases in both glomerular 
hydrostatic pressure and in the filtration coefficient, which is a function 
of the glomerular surface area and permeability (Atlas and Maack, 
1987). Also, the effect may result from an increase in total renal blood 
flow as a consequence of afferent arteriolar dilation together with mild 
constriction of efferent arteriolar constriction within renal glomeruli 
(Adams 1987). 
ANP also appears to modify intrarenal hemodynamics in such a 
way as to increase blood flow through the inner medulla and the papilla 
(Winquist 1987; Ballerman and Brenner, 1985; Adams 1987). This 
leads to impaired reabsorption of Na+ in the papillary portion of-the 
ascending limb of the loop of Henle. Coupled with the increase in GFR, 
diuresis and natriuresis will result. 
III. Effects on hormone release 
ANP blocks the release of several classes of hormones all of 
which are involved in blood pressure and volume regulation. These 
include aldosterone, renin and vasopressin. 
ANP significantly decreases aldosterone secretion from adrenal 
glomerulosa cells. The inhibition seems to occur at the early stage of 
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conversion of cholesterol to pregnenolone (Samaon 1987). • 
ANP also inhibits renin release from the kidney (Atlas and 
Maack，1987; Winquist 1987). However, the mechanism is not clear 
and this action can be overcome in certain experimental situations such 
as renovascular hypertension or when ANP induces a major decrease in 
blood pressure. 
In addition, ANP can block vasopressin release from the posterior 
pituitary. The effect is probably mediated at the level of the 
vasopressin-producing cells within the hypothalamus (Samson 1987). 
BNP also exerts a suppressive effect on angiotensin-stimulated 
secretion of aldosterone, on basal aldosterone secretion and on Cortisol 
secretion in response to ACTH (Hashiguchi et al” 1988). Since BNP is 
as potent as a-hANP in inhibiting steroidogenesis in bovine 
adrenocortical cells, it may act on the adrenal in the same manner as a-
hANP. 
IV. Central Effects 
Immunocytochemical studies show that ANP immunoreactivity is 
widespread in the CNS, especially in regions such as anteroventral third 
ventricle of the hypothalamus (Tanaka et al., 1984) and the subfornical 
organ (Saacedra et al.，1986) which are intimately involved in central 
regulation of cardiovascular function and electrolyte and water balance. 
Intracerebroventricular infiisions of ANP inhibit vasopressin secretion, 
and suppress angiotensin II induced water consumption. The 
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antidipsogenic action of ANP is shared with centrally administered 
BNP (Itoh et al” 1988). Thus, natriuretic peptides appear to act in the 
central, and perhaps the peripheral, nervous system as 
neurotransmitters or neuromodulators to inhibit water intake. This 
action may act in concert with the renal actions to influence volume and 
salt reduction. 
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5«5 Natriuretic Peptide Receptors And Second Messengers • 
The diverse actions of natriuretic peptides appear to be mediated 
by specific receptors on the cell membrane. Following receptor binding 
they operate through a variety of second messenger systems to induce 
their effects in specific target cells. 
I. Receptor subtypes of natriuretic peptides 
To identify natriuretic peptide receptors, specific binding of 
radiolabeled peptides^ to membrane preparations or cultured cells of 
different tissues has been used (Leitman and Murad, 1987). Scatchard 
analysis of binding data reveal a single class of high affinity receptor 
with a K^ in the nanomolar range (Leitman and Murad, 1987). 
However，truncated analogues of ANP such as API (a 21 amino acid 
analogue of rANP without the carboxy terminal phe-arg moiety) and C-
ANP(4.23) ([des-GlnlS, Serl9, Gly20, Leu^l, Gly22]ANP(4.23) a 
synthetic ring-deleted analogue ofhANP which binds with high affinity 
to the ANP-C receptor, but with very reduced activity, about 3 order of 
magnitude lower than ANP) have also been shown to bind with foil 
capacity despite limited biological activity (Balleraian and Brenner, 
1985; Leitman et al.，1986). These data raise the possibility of at least 2 
different populations of receptors. Cross-linking experiments reveal that 
tissues such as adrenocortical cells and endothelial cells (Leitman et al.， 
^ Both ANP and BNP can be iodinated with However, CNP cannot be directly 
iodinated since CNP does not have tyrosine residue. Therefore, radiolabeled CNP is made by 
iodinating synthetic Tyr^-CNP by lactoperoxidase method. 
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1986; Takayanagi et al” 1987) contain 3 types of receptor of different • 
molecular weight: one with a MW of 66 kDa, one 135 kDa and one 180 
kDa. Separation and purification of the two receptors leads to the 
conclusion that the 135 kDa receptor contains guanylate cyclase activity 
and is not reducible by dithiothreitol while the 66 kDa receptor is 
devoid of guanylate cyclase activity. The 180 kDa receptor is a dimer 
of the other 2 receptor subunits associated through a disulfide bond 
(Leitman and Murad, 1987; Leitman et al.，1986). 
The 135 kDa receptor is tightly coupled to a membrane form of 
guanylate cyclase (Takayanagi et al” 1987), which can produce an 
increase in intracellular cyclic GMP - a putative second messenger for 
natriuretic peptides. (Leitman and Mirad, 1987; Waldman et al., 1986). 
Subsequent evidence that the particulate guanylate cyclase isolated 
from rat brain demonstrates ANP binding and guanylate cyclase activity 
(Chinker et al., 1989)，and that ANP binding and particulate guanylate 
cyclase activity copurify from lung (Kuno et al.，1986) confirm that 
guanylate cyclase is an integral part of the 135 kDa receptor molecule. 
This receptor-guanylate cyclase represents a form of signalling system 
in which the second messenger systems are directly stimulated by the 
receptor protein in response to agonist binding; analogous to the 
insulm-protein tyrosine kinase system. 
The 135 kDa receptor has a stringent structural requirement for 
ligand binding. Only those analogues possessing the carboxy terminal 
phe-arg moiety are capable of stimulating guanylate cyclase (Leitman et 
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al” 1986; Currie et al., 1984). It is believed that this receptor mediates -
many of the biological actions of ANP using cGMP as a second 
messenger. It has been designated as ANP-B receptor. 
Recently, the material originally termed ANP-B receptor has 
been cloned and sequenced (Chang et al” 1989; Chinker et al” 1989). 
Molecular cloning studies have identified two subtypes of natriuretic 
peptide receptor guanylate cyclases within the moeity originally termed 
as B receptor. They are now differentiated into ANP-A (A-type) and 
ANP-B (B-type) receptors. ANP-A receptor responds similarly to ANP 
and BNP while ANP-B receptor is preferentially activated by BNP 
(Chang et al” 1989). However，CNP, does not increase cGMP within 
the cells such as COS-7 which have been transfected with ANP-A 
receptor only (Roller et al” 1991). The affinity of CNP for the ANP-B 
receptor is higher than both ANP and BNP in tissues such as aortic 
smooth muscle cells and mesangial cells where the predominant form 
of biological active receptor is the ANP-B receptor (Suga et al” 1992). 
In contrast, the 66 kDa receptor is a guanylate cyclase free 
receptor and is less sensitive to changes in natriuretic peptide structure. 
Analogues sequentially truncated at the amino or carboxyl termini to 
the 17-member ring core and even acyclic analogues (CANP(4_23)) all 
show high affinity for these receptors (Scarborough et al., 1987). Such 
shortened analogues have been used as probes to discern the function of 
this 66 kDa receptor. In vitro and in vivo studies led Maack et al. 
(1987) to advance the hypothesis that this cyclase-free receptor is a 
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clearance receptor whose function is to absorb excess ANP and either to 
eliminate it from the circulation or to store and slowly release it， 
thereby buffering circulating ANP levels . These receptors have been 
termed ANP-C receptors to denote their suggested role as clearance 
receptors. Recently, the ANP-C receptor has also been sequenced, 
cloned and expressed (Fuller et al.，1988). Binding studies with other 
natriuretic peptides have demonstrated that it recognises all natriuretic 
peptides including . CNP. It consists of a large acidic extracellular 
domain and a single potential transmembrane domain with a short 37-
amino acid cytoplasmic tail (Fuller et al., 1988). 
The ratio of ANP-B to ANP-C receptor varies extensively from 
tissue to tissue (Leitman et al” 1988; Pandey et al., 1988). The 
overwhelming majority of receptor in solubilized membrane 
preparations from lung and aortic smooth muscle cells is classified as 
clearance receptor. In endothelial cells, ANP-C receptors range from 
72% (Suga et al., 1992) to over 95% (Leitman et al.，1988; Pandey et 
al.，1988) of total ANP binding sites. An attractive explanation for the 
abundance of ANP-C receptor in vascular tissues has been put forward 
by Inagami (1989). A sudden surge of ANP in response to acute 
hypotension may endanger life by unduly reducing blood flow. The 
high density of clearance receptor may help to buffer such sudden 
surges in ANP secretion. Organs such as adrenal cortex or testis may be 
less vulnerable to such effects, and therefore the proportion of clearance 
receptor is lower. 
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n. Second Messengers of natriuretic peptides 
A relation between ANP receptors, guanylate cyclase and cGMP 
was suggested by the observation that these peptides increased cGMP in 
kidney (Leitman and Murad, 1987; Hamet et al” 1984; Waldman et al., 
1984). Natriuretic peptides have also been demonstrated to activate 
particulate guanylate cyclase in membrane preparations of several rat 
tissues in a dose-dependent manner (Waldman et al., 1984). BNP and 
CNP are able also to stimulate cGMP production in tissues where ANP 
has an effect (Iwata et al., 1989; Song et al., 1988; Kohno et al” 1992). 
Although it is generally accepted that cGMP is a second 
messenger mediating natriuretic peptide actions, it is not clear if all 
actions can be explained by this mechanism. There is evidence that 
ANP may use other second messenger systems. In adrenal zona 
glomerulosa cells, ANP elicits vigorous production of cGMP, and 
inhibition of aldosterone synthesis occurs. However, sodium 
nitropmsside - an agent which can also induce cGMP production, and 
several permeable derivatives of cGMP such as 8-bromo-cGMP (Br-
cGMP) and 8-chlorophenylthio-cGMP, do not inhibit aldosterone 
release (Inagami 1989). 
It has been reported that ANP induces breakdown of 
phosphatidylinositol phosphates and generation of inositol phosphates 
in vascular smooth muscle cells (Resind et al., 1988). However, this is 
not consistent with the finding that ANP causes vasorelaxation by 
lowering intracellular Ca2+ (Leitman and Murad, 1987) as an increase 
Page 26 
Chanter s： Review nfT.itPmt… 
in inositol phosphates will normally be expected to be followed by an 
efflux of Ca2+ from intracellular sources. ANP has also been shown to . 
inhibit cyclic AMP production by inhibiting adenylate cyclase (Anand-
Scarivastava et al., 1986). 
Furthermore, serious discrepancies exist in some tissues, for 
example mouse astrocytes as studied by our group (Yeung et al., 1991)， 
between the binding affinity and the concentration of peptide required to 
elicit a cGMP response. The latest findings from a newly discovered 
antiproliferative action of natriuretic peptides, indicate that this effect is 
not mediated by cGMP as the 'inactive' C-ANP(4_23) analogue has been 
shown to inhibit thymidine incorporation with similar potency to ANP 
and BNP (Levin and Frank, 1991). Therefore, it suggests that the so-
called clearance receptor is physiologically active and activates a still 
unidentified second messenger system. This issue is addressed further in 
this thesis (see chapter 9.3, page 144) where additional results will be 
presented and discussed. 
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5-6 Clinical Implications of Natriuretic Peptides 
The natriuretic peptides have provided many challenges to 
biochemists, physiologists and also clinicians. Areas of clinical interest 
include potential diagnostic and therapeutic roles for these peptides. 
I. Diagnostic role of ANP 
In clinical studies, measurement of plasma ANP may prove to be 
a useful marker of intravascular volume status or cardiac strain. For 
example, raised plasma ANP concentrations are seen when atrial 
pressure is elevated due to cardiac dysfunction or as a result of a 
disturbance of sodium and water balance. A transient rise in plasma 
ANP is associated with episodes of paroxysmal atrial tachycardia 
(Crozier et al.，1987). Plasma ANP is elevated in patients with 
congestive heart failure and the increase is parallel to the severity of the 
disease (Raine et al.，1986). Furthermore, circulating ANP is raised in 
some patients with chronic renal failure (Wilkins et al” 1987) and 
essential hypertension, most notably those with left ventricular 
hypertrophy (Montors et al” 1987). Of interest is the finding of chronic 
elevation following cardiac transplantation, even in the absence of overt 
heart failure (Burnett 1987). 
II. Therapeutic Value of ANP 
As a therapeutic agent, ANP is potentially unique in its actions. It 
has diuretic and natriuretic actions mainly due to direct effect on the 
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kidney and these actions can be maintained even under hypotensive 
conditions (Needlemen and Greenwald, 1986). Moreover, it does not 
lead to any significant potassium loss (Richards et al” 1985b). These 
properties may be exploited in the management of heart failure, renal 
failure and hypertension. 
ANP may prove useful for reducing the frequency of dialysis in 
patients with chronic renal failure. Parenteral administration of ANP in 
patients with essential hypertension results in a rapid but transient fall 
of blood pressure (Richards et al., 1985a). Normal blood pressure can 
be maintained for days in hypertensive rats following intravenous 
infusion of ANP. It has a distinct advantage over other diuretics as it 
can increase GFR even in the presence of reduced blood pressure and 
renal blood flow. However, intravenous infusion of ANP can induce or 
potentially worsen proteinuria in patients with essential hypertension 
(Suenaga et al.，1989)，chronic glomerulonephritis (Hirata et al., 1991) 
and non-insulin dependent diabetes mellitus (Chan et al., 1992). ANP 
may increase protein excretion by a similar mechanism to that which 
elevate GFR or by increasing glomerular permeability (Hirata et al., 
1991). 
Currently, most clinical studies use native ANP. The effect, 
though rapid, is of very short duration. Various approaches are under 
investigation for prolonging its action. Analogues with a longer 
duration of action are currently being sought, for example chemically 
altered peptides which can resist degradation. Drugs which can inhibit 
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the activity of enzymes involved in the degradation of circulating ANP . 
may also be of value, as may agents that can stimulate the synthesis and 
release of endogenous ANP. 
Recently, natriuretic peptides have been found to inhibit cell 
proliferation in tissues such as smooth muscle cells (Abell et al., 1989)， 
kidney mesangial cells (Appel 1988) and rat astrocytes (Levin and 
Frank，1991). They may therefore prove usefiil in such condition as 
atherosclerosis, vascular internal proliferation and cardiac hypertrophy, 
and allow a potential therapeutic role similar to angiotensin converting 
enzyme inhibitors. 
It is possible that situations may exist in which excessive ANP 
activity is harmful. Glomerular hyperflltration may be a major factor 
linked to the development of diabetic glomerulopathy (Ortola et al.， 
1987). Although the issue is controversial, increased ANP 
concentrations have been linked to glomerular hyperflltration in 
diabetic rats (Ortola et al.，1987; Zatz et al” 1985) and may contribute 
to proteinuria. Administration of antiserum to ANP decreased GFR in 
these animals (Ortola et al., 1987), raising the possibility that ANP 
antagonists may decrease the progression of renal disease in diabetic 
patients. 
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5.7 Review on Astrocytes 
5.7.1 Historical background 
Virchow (1846) first recognised neuroglial cells and fibres in the 
ground substance of the CNS. He coined the term 'neuroglial' to 
describe the regions between neurons that he considered analogous to 
the cementing connective tissue seen in other bodily organs. When the 
Italian cytologist, Golgi developed a new staining technique based on 
metallic impregnation, neuroglia were demonstrated to consist of a 
distinct class of non-neuronal cells. Subsequently, Cajal (1913) carried 
the staining method further by developing a highly selective gold 
chloride-sublimate method and was able to demonstrate the complete 
outline and integrity of astrocytes. He also identified another group of 
smaller, faintly stained non-neuronal cells which were later 
characterized as oligodendroglia by Del RioHortega (1919). 
With the development of astrocyte cell cultures, our knowledge 
of astroglial cell characteristics and physiological functions in the CNS 
has increased substantially. Astrocytes are now known to be 
metabolically highly active cells which possess transporters for the 
active uptake of amino acids and many enzyme systems for their 
metabolism (Hansson, 1988). They also have mechanisms for the active 
transport of ions such as K+ which is increased after neuronal activity, 
and which help to regulate the extracellular environment of neurons 
(Heim et al., 1972; Hertz 1978). A wide range of neurotransmitter and 
neuropeptide receptors, which were originally found in neurons, have 
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also been shown to be expressed on astrocytes (Murphy and Pearce, “ 
1987). It has now been demonstrated clearly that astrocytes have a very 
important role in the maintenance of normal physiology and 
metabolism, in brain development and in the pathological responses of 
the nervous system to injury. Interactions between astrocytes and 
neurons are important for normal neuronal function and metabolism. 
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S.12 Types of Astrocytes 
Traditionally, astrocytes have been categorized as 'protoplasmic' 
or Yibrous, (fibrillary). Protoplasmic astrocytes are found 
predominantly in the cortical grey matter (Tedeschi, 1970), whereas 
fibrous astrocytes tend to be more numerous around blood vessels and 
in sub-ependymal regions (Duffy, 1983). This classification is based on 
morphological appearance. 
Raff and Miller (1984) introduced a new classification, based on 
the immimocytochemical staining properties of astrocytes, in which 
astrocytes are divided into type I and type 11. Type I astrocytes have a 
fibroblast-like morphology and do not bind tetanus toxin (Van 
Heyningen, 1963) or A2B5 monoclonal antibody (Raff et al, 1983). 
Type II astrocytes have a process-bearing appearance and bind both 
tetanus toxin and A2B5 antibody (Raff et al, 1983). The majority of 
astrocytes in grey matter have a type I phenotype, whereas the majority 
in white matter have type II characteristics. It appears that type I and 
type II astrocytes correspond morphologically to protoplasmic and 
fibrous astrocytes (Miller et al., 1985). There are also some specialised 
forms of astrocytes such as Muller glia and Bergmann glia. 
Despite variations in morphology, all forms possess glial 
fibrillary acidic protein (GFAP). It is a component of the intermediate 
glial filaments and is found only in astrocytes. It has proved to be a 
valuable marker for identifying astrocytes. Thus, anti-GFAP antiserum 
is widely used in studies of astrocytes, e.g. in cell cultures, as a marker 
of the purity of the preparation (Bignami et al., 1972; Malhortra, 1987). 
Page 33 
Chapter 5; Review nf Literatiirp 
5.7.3 Regulation of central ionic concentrations 
The ionic composition of the region around neurons is critical for • 
their effective functioning. The flows of sodium and potassium ions are 
responsible for the generation of action potentials, and the levels of 
these ions, particularly potassium ions, is finely regulated. 
During neuronal activity, extracellular K+ concentration is 
increased. The K+ ions are then cleared by the action of astrocytes. 
These ions may then diffuse through glial syncytia to the extracellular 
milieu of inactive neurons (Dietzel et al” 1980; Gardner-Medwin, 
1983). The concept of spatial buffering of K+ ions was introduced by 
Kuffler et al. (1966). They hypothesized that the high K+ permeability 
of astrocytes, coupled with their low-resistance intercellular 
connections, would permit them to transport K+ from areas of high 
concentration to areas of normal K+. Such regulation of the neuronal 
microenvironment by astrocytes acts to stablize the extracellular milieu 
and helps to buffer the activity of neurons which may otherwise affect 
environment of other nearby neurons, especially where they are densely 
packed. 
Several morphological and physiological adaptations are found in 
astrocytes which assist their role as regulators of extracellular K+. 
Firstly, astrocytic processes have intimate associations with synaptic 
regions where the greatest fluxes of ions occur (Ariyasu et al., 1985). 
Secondly, permeability to K+ is highest in the end feet of the processes 
(Newman, 1986). Also, Na+-K+ ATPase activity has been found to 
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increase as a result of increased extracellular K+ (Cummins et al” “ 
1979). Thirdly, the presence of K+ channels facilitate its removal. 
Several types of K+ channel seem to be involved (Bevan and Raff, 
1985). The voltage-gated CI" channel (Gray and Ritchie, 1986) and 
voltage-dependent K+ channels are the most important (Bevan and 
Raff，1985). In addition, the Na/K/Cl cotransporter is activated in 
response to an increase in K+ in cultured astrocytes (Walz and Hinks, 
1985) and in cultured glioma cells (Winter-Wolpaw and Martin, 1984). 
These in vitro observations suggest that this cotransport system may 
participate in K+ removal in vivo. 
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5.7.4 Amino acids and energy metabolism 
In order for the neuronal network to function smoothly, 
neurotransmitters such as glutamate, aspartate and y-aminobutyric acid 
(GABA), after being released into the synaptic cleft, must be removed. 
Glutamate and aspartate are major excitatory amino acids in the CNS, 
whereas GABA is inhibitory. It is now clear that some transmitters are 
removed into astrocytes. Enzyme systems (glutamine synthetase) are 
present in astrocytes to metabolize both GABA and glutamate. 
Glutamate is converted to glutamine by the action of giutamine 
synthetase, which is found exclusively in astrocytes. The glutamine is 
then transported to neurons, where it becomes the substrate for ftuther 
GABA and glutamate synthesis and release as transmitter again. 
Astrocytes are also capable of utilizing glutamate for energy production 
(Yu et al.，1982). Glutamate may be converted to a-ketoglutarate which 
can be oxidized to CO2.. Neurons, however, are unable to use 
glutamate in this way (Schousboe et al.，1985). 
The rapid removal of these transmitters appears to be mediated 
by active uptake by high affinity carriers (Hansson, 1988). Astrocytes 
from different regions of the brain show different abilities to take up 
glutamate, aspartate and GABA. The differences reflect to some extent, 
regional neuronal activity (Drejer et al., 1982; Hansson et al., 1985; 
Wilkin et al.，1983) as well as the capacity of astrocytes to metabolize 
amino acids in different brain regions (Hallermayer and Hamprecht, 
1984; Hansson, 1988). 
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Energy for this active removal process is in part derived from 
oxidation of glucose. Of the total amount of glucose entering the 
glycolytic pathway in astrocytes, up to 50% is converted to lactate 
which constitutes the major oxidative substrate in the CNS (Larrabee, 
1983; Yu and Hertz, 1983). Approximately 10% is converted to 
glycogen (Cummins et al” 1983). Astrocytes are a major site of 
glycogen storage in the brain (Cataldo and Broadwell, 1986). Their 
glycogen content can be influenced in vitro by various 
neurotransmitters, neuropeptides and hormones. 
Cultured astrocytes exhibit glycogenolysis in response to a 
number of neuromodulators such as noradrenaline (Quach et, 1978) 
and vasoactive intestinal peptide (VIP) (Magistretti et al., 1981). 
Glycogenolysis would provide cells with ATP and metabolic substrates 
in the form of glucose-6-phosphate, pyruvate and lactate, and would be 
a mechanism for coping with increased energy demand. These 
substrates may be utilized by the astrocytes themselves or transported to 
neighbouring neurons (Shank and Campbell, 1984). It is possible that 
both neurons and astrocytes increase their demand for these metabolic 
substrates following increased neuronal activity; astrocytes to remove 
extracellular K+ and amino acids, and neurons to remove intracellular 
Na+ (Orkand, 1986). In support of this hypothesis are the findings that 
astrocytes possess glucose-6-phosphatase (Cataldo and Broadwell, 
1986)，can release glucose, pyruvate, lactate and a-ketoglutarate and 
have been reported to increase glucose release in response to 
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noradrenaline (Cambray-Deakin et al., 1988). Glycogen synthesis and 
glucose uptake, on the other hand, is increased in response to insulin in 
mouse astrocytes (Kum et al., 1992). 
In addition to responding to a generalized metabolic demand, 
astrocytes may be capable of responding to highly localized demands. 
Magistretti et al. (1981) have proposed that activation of the 
noradrenergic system together with activation of VIP will cause 
potentiation of cAMP and glycogenolytic responses in astrocytes. This 
will have the effect of producing metabolic�hot spots' to cope with 
localized increases in neuronal activity. 
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SnJS Astroglia] membrane receptors 
A wide range of membrane receptors for neurotransmitters and 
neuropeptides have been demonstrated on astrocytes (Cholewinski et 
al.，1988; Murphy and Pearce, 1987; see also Table 5.7.5.1). Most of 
these receptors were originally found on neurons and have now been 
identified on astrocytes. B-Adrenergic receptors are expressed on 
astrocytes and receptor activation leads to increased cAMP production 
(Hertz et al” 1984). In addition, astrocytes in culture possess a2-
adrenergic receptors, which mediate an inhibition of cAMP 
accumulation within the cells (McCarthy and DeVellis, 1978). 
Receptors for excitory and inhibitory amino acids also exist on 
astrocytes. Examples are GABA receptors (Stephenson, 1988), N-
methyl-D-aspartate (NMDA) receptors (Condorelli et al., 1987) and 
glutamate receptors (Glaum et al., 1990). 
In addition to these neurotransmitters, receptors for a wide range 
of peptide hormones are present. These receptors can be divided into 
several classes according to the second messenger system they couple 
to. There are receptors that couple to adenylate cyclase. Vasoactive 
intestinal peptide (VIP) receptors may be the best documented example 
of peptide receptors on astrocytes (Koh et al., 1984; Wilkin and 
Cholewinski, 1988). Other peptides such as secretin (Van Calker et al” 
1980), somatostatin (Van Calker et., 1980), glucagon (Koh et al, 1984) 
and opioid peptides (Rougon et al” 1983) have all been shown to bind 
to specific receptors on astrocytes and affect cAMP production 
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mediated by adenylate cyclase. Moreover, it has become clear that “ 
astrocytes are capable of receptor-mediated effects on inositol 
phospholipid metabolism. Pearce and Murphy (1988) demonstrated that 
noradrenaline (via the a i-adrenergic receptor), carbachol (via the 
muscarinic cholinergic receptors), glutamate and serotonin can all 
activate phospholipid breakdown. Cholewinski et al. (1988) in another 
study examined the action of a number of neuropeptides on 
phospholipid metabolism and showed a unique pattern of 
responsiveness exhibited by astrocytes from different regions of the 
brain. 
Although the cGMP second messenger system is not as well 
documented as the former two systems, it has been consistently 
demonstrated that guanylate cyclase, both in soluble and membrane 
bound forms, is present in astrocytes (Zwiller et al., 1981). Also, 
cultures of astroglia (Bloch-Tardy et al” 1980; De Vente et al., 1989; 
Friedl et al., 1989; Yeung et al.，1991)，glioblasts (Turiff and Lim, 
1979) and glioma cells (Kon and Breckenridge, 1979; Lyall et al., 
1988) synthesized cGMP in response to various stimuli, including 
natriuretic peptides. The atrial, brain and C-type natriuretic peptides 
have all been shown to bind to specific membrane receptors and to 
cause cGMP production (Yeung et al.，1991; Yeung et al., 1992). The 
consequences of this increased level of cGMP are as yet unknown and 
this issue will be discussed further later in the thesis (see chapter 9 for 
biological actions of natriuretic peptides). 
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^ ^ ^ ^ ^ CeHsstudted Effects Referencs 
DopaninQ/Dopamine GBalceflsfrom A c t i v e of Palmer 1978 
various brain areas adenyl^ cydase ^ 
Hlstamine/H2 ^ j ^ c ^ o f •"crease m cAMP VanCaflcer 
etaL,ig77 • 
Noradrenalina® Rat glioma C6 Incraase in cAMP Glln«n and Nirent«ra. 
1971 
Wofphological Oey. 1975 
dSferentiation 
Increased LDHactivty Bottenstein m i 
deVetts, 1978 
iJJ^ raased Browning et ai.. 1974 
giycogenolysis 
fnoBasedNa/KnMPase NaiumietaL. 1978 
C3f astTDWasts ac&vfty 
Increased cartjonic NanmetaL. 1978 
anhydrase activity 
！;^^gf iona 丨 ncraasemcAMP Edstrom et aL, 1975 
Human astrocytoma Increased inositol Johnson etaL 1969 
/SubstenceP ceflsUCIIMG phosphate formation • 鄉 
VIP/VIP receptor Primary cutture of increase in cAA/B' Omenvoiss et aL 1965 
mouse astrocytes 
P f l m ^ cuttufB Increase in cAMF M^istretti et aL. 1963 
rat astiDcytss 
Secreen/Secrefin Primary cultures of Increase in cAMP Van Cafcer etaL 1980 
mouse astrocytes , 
Somatostatin Primary cultures of Inhibit cAMP sfimdated Van CdkeretaL 1980 
'somatostatin mouse astrocytes by VIP and secretin 
Met-enkephalin Rat astrocytes Inhibit cAI^ sdrm^atsd RougonelaL. 1963 
/opiate receptor by noradrenaine 
ANP/natriuratic RatgiomaC6 Incrsese in cGMP FriedletaL. 1985 
peptide receptors 
Human astiouytmiia Increase in cGMP Lyal et aL. 1968 
C8«S(U373MG) 
Primary cufajras of Increase in cGMP TeohetaL. 1989 
mouse astrocytes 
pBNP/naWureOc Primary cuttures of Increase in cGMP YeungetaL. 1991 
peptide receptors mouse astrocytes 
rfiNP/natriuratic Primary ailures of Increase in cGMP Beaumont and Tan. 1991 
peptide receptore rat astnxytes 
CNP/natriuretic Primary cultures of InoBase in cGMP Yeungetal.. 1992 
peptide receptDfB mouse astrocytes 
Insuiin/insuiin Primary cuttures of Increased pynmidine nudeoside Kum et aL. 1987 
mouse astrocytes uptake and inoorporafion 
Human astrocytoma Increased uridine inoorporation Kum et al., 1989 
calls (U373MG) 
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5.7.6 Astroglia] Heterogeneity 
There is increasing evidence that astrocytes are a heterogeneous 
class of cells in terms of morphology, biochemistry and fiinction. This 
heterogeneity is indicated by different concentrations of GFAP and 
glutamine synthetase (GS) found in astrocytes from different regions of 
the CNS (Patel et al., 1985). Corpus striatum and spinal cord contain the 
lowest concentrations of GFAP and GS activity, whereas the olfactory 
bulb shows the highest concentrations. Immunochemical studies on 
whole tissue homogenates from different brain regions support the 
evidence provided by variations in GS activity and GFAP 
concentrations. Also, regional differences exist in their ability to 
express vimentin in cultures (Hansson, 1986). 
Concerning the expression of membrane receptors, primary 
cultures of astrocytes from various regions have also shown differences 
in both the types of receptors as well as their affinity (Hansson, 1988). 
Burgess et al. (1985) demonstrated a varied pattern of distribution of 
beta-adrenergic receptors in astrocytes from different regions. There is 
also evidence indicating cellular heterogeneity of serotonin (Hansson et 
al” 1987), dopamine (Hosli and Hosli, 1986) and VIP (Hansson and 
Ronnback, 1988) receptors. 
In addition, primary cultures of astrocytes from different regions 
show differences in functional responsiveness to a variety of stimuli 
(Murphy and Pearce, 1987). A differential dopamine-stimulation of 
adenylate cyclase in cortical and striatal, but not in brainstem astrocytes 
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has been demonstrated (Hansson et al” 1984)，whereas there is 
differential inhibition by somatostatin of adenylate cyclase in astrocytes 
derived from striatum, mesencephalon, and cerebral cortex (Chneiweiss 
et al•，1985). Carbachol stimulates inositol phosphate production in 
primary astrocytes cultured from the mesencephalon but not from 
corpus striatum or cerebral cortex (El-Ettr et al., 1989). A study of the 
differential sensitivity of cAMP and inositol phosphate production to a 
variety of peptides in primary cultures from rat forebrain, cerebellar 
cortex and spinal cord (Cholewinski and Wilkin, 1988) further supports 
Ae concept of regional heterogeneity of astrocytes. Recently, astrocytes 
in situ have also been shown to demonstrate heterogeneity with respect 
to the cGMP response to ANP and sodium nitroprusside (De Vente et 
al., 1990). However, primary cultures of neonatal mouse astrocytes 
derived from cortex, cerebrum and hypothalamus do not demonstrate 
different binding characteristics or cGMP production in response to 
either ANP or BNP (Yeung et al., unpublished observations). 
The regional specialization of astrocytes may serve to meet the 
neuronal demand in the vicinity. This view has received support from 
differences in the active uptake of glutamate，aspartate and GABA, and 
the ability to metabolize these in various regions which correlate with 
neuronal activity (Drejer et al., 1982; Hansson et al., 1985; Wilkin et 
al” 1983). However, this remains a poorly understood area of astrocytic 
physiology. 
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6. General Materials and Methods 
6.1 Sources of Chemicals 
Human ANF(i_28) (a-hANP) and rat ANP(i-28) (rANP(i-28)) 
were purchased from Bachem (Switzerland). Porcine BNP (pBNP) and 
CNP was purchased from Peninsula Laboratory (U.S.A.). Dibutyryl 
cyclic AMP (dbcAMP), HEPES and bovine serum albumin (BSA) were 
obtained from Sigma (U.S.A.). Horse serum, amino acids, L-glutamine 
and pencillin/streptomycin were purchased from Gibco Laboratories 
(USA). Culture dishes and flasks were from Falcon Labware (USA). 
62 Culture of mouse astrocytes 
6.2.1 Principle of culture 
Primary cultures of mouse astrocytes were prepared according 
to tihe method of Hertz et al. (1978) with some modifications (Kum et 
al” 1987) developed in our laboratory. 
1 to 2 day-old neonatal mice were decapitated with scissors. 
Astrocytes from the cortical region were cultured. The subependymal 
germinal plates from the lateral ventricles of the mouse brains were 
dissected using an aseptic technique. The tissues were homogenized and 
vortexed to disperse large aggregates. The cell suspensions were 
distributed at a seeding density of 1 x 10^ cells/cm^ into 35-mm-
diameter culture dishes containing Minimal Essential Medium (MEM) 
with a double concentration of all amino acids except L-glutamine (2.8 
mM), a quadruple concentration of Minimal Essential Medium vitamin 
solution，20% horse serum, 200 lU/ml of penicillin, and 200 jig/ml of 
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Streptomycin. Differentiation of astrocytes into the process-bearing . 
form was induced at confluence (12-14 days of culture) by addition of 
0.25 mM dibutyiyl cyclic AMP (dbcAMP) in MEM supplemented with 
10% horse serum. The cells were allowed to grow in this medium for a 
fiirther two weeks before use in experiments. During the course of 
culture，astrocytes were kept in an incubator at 370C and pH was 
maintained at 7.3 by CO� . Regular monitoring with indirect 
immunofluorescence using anti-glial fibrillary acidic protein (GFAP) 
antiserum showed that more than 95% of the cells were GFAP positive. 
6.2.2 Methods 
6.2.2.L Dissecting tools - straight scissors 
-straight fine scissors 
-curved fine scissors 
-small curved forceps 
-syringes (10ml x2,30ml xl) 
-small pins 
-beaker (100ml) 
622Ai, Sterilization procedure 
All dissecting tools were sterilized by heating to 150X for 90 
minutes. A 10 micron filter was sterilized by autoclaving in a 
humidified chamber at 120'C, 15 psi for 30 minutes. 
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6.2.2.iii. Preparation of medium • 
MEM (Cat. No. 410-1 lOOEL) was used to prepare the medium. The 
exact procedure is as follows: 
a. Measure out deionized distilled water to a total volume equal to 5% 
less than the final required volume of the medium, using a mixing 
container that is as close to the final volume as possible. 
b. Add powdered medium to the water with gentle stirring. 
c. Rinse out the inside of the package to remove all traces of powder. 
d. Add 2.2 g of NaHCOs Per litre of medium 
e. Dilute to the desired volume with water and stir until dissolved 
f. Adjust the pH (by IN NaOH or IN HCl) of the medium to 0.2-0.3 
pH units below the desired final working pH 
g. Keep the container closed until the medium is filtered. 
h. MEM is sterilized immediately by membrane filtration (positive 
pressure recommended) and kept in sterilized bottles. . 
i. For 10% serum supplemented MEM, 50 ml of horse serum is added 
to 450ml of MEM; and for 20%, 100ml of horse serum is added to 
400ml of medium. 
j. To each bottle of medium, 10ml of MEM amino acids solution, 15 
ml of MEM vitamins, 10 ml of pencillin/stretomycin and 2ml of L-
glutamine is added. 
k. The pH of the medium (pH7.2-7.4) is adjusted by adding 
appropriate amount of IN NaOH. 
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6.2.2.iv. Dissection of mice 
a. Clean the heads of the mice with 70% alcohol 
b. Decapitate the mice with the large scissors. 
c. Place the heads on a small paraffin block wrapped with sterile 
gauze. 
d. Fix the heads by pinning near the nose and the neck. 
e. Cut the skin with fine straight scissors and remove it with forceps 
f. Cut open the skull in the middle with a new pair of straight 
scissors 
g. Carefiilly remove the skull with blunt curved forceps to expose 
the cerebrum 
h. Remove the cerebellum and the olfactory bulbs with fine curved 
forceps 
i. Cut out the cortical hemisphere with fine curved scissors 
j. Expose the underside carefully on the gauze and cut only the inner 
region of the thalamus 
k. Transfer the tissue to a culture and homogenize it by vigorous 
cutting and grinding with scissors 
1. Add 5 ml of culture medium to the tube and vortex it for 20-30s 
m. Filter the cell suspension through a 10 micron sterile membrane 
filter to a beaker, 
n. Rinse the culture tube with another 5 ml medium and filter it 
0. Add the appropriate amount (the seeding density about 104 
cells/cm^) of medium to the beaker and distribute it to culture 35-
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nm-diameter dishes using a syringe 
p. Incubate the dishes in a 5% CO2 /95% air humidified incubator 
6.2.3 Culture conditions 
Astrocytes were cultured with 20% horse serum supplemented 
MEM for the first two weeks. The medium was changed twice weekly. 
At confluence (about two weeks after seeding), astrocytes were 
switched to 10% horse serum supplemented MEM with the addition of 
dbcAMP at a concentration of 0.25mM to stop proliferation and induce 
differentiation. The astrocytes were maintained in these conditions for a 
further two weeks. They were ready for experiments after about 30 days 
of culture. 
6.2.4 Validation of astrocyte culture preparations 
Photograhs 6.2.4.1-6.2.4.8 show different stages of development 
of mouse astrocytes in culture. Astrocyte cultures were monitored with 
indirect immunofluorescence using anti-GFAP antiserum. More than 95 
% of the cells in cultures were shown to be GFAP positive. 
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Mouse astrocytes. 3 davs in culture, phase contrast rxlQOI 
m 
astrocv*^ ,^ 7 davs in culture, phase rmtm^ MOQ) 
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ffoiise astrocytes. 11 davs in culture, phase contmRt ( j ] (ffl) 
m 
Mouse astrocytes at confluence. 14 davs in cultures, addition ofdbcAMP 
starts, phase contrast (^100� 
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Mnme astrocytes. 17 davs in cultures. 3 davs after dbcAMP treataent phase 
contrast (xlOO) / 
• 
Mouse astrocytj^s 21 days in culture, 7 davs nfter aflHition of dhcAMP^ptose 
contrast (xlOO) 
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Mouse astrocytes, 24 davs — culture, 10 davs culture witfa dbcAMP, vhm. 
contrast rxlOO^ 
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• 
Mouse astrocytes. 28 davs m cultures, ready for experiment pha^e crmtrafst 
oam 
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Mouse asfrocytes 4 davs post-confluence (18 davs m culture), phase cpntr^ 
visible light (xlOOl 
議 
Mouse astrocytes 4 davs post-confluence after GFAP stammg. phase contrast 
UV (xlOO) Page 53 
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丨 M W i 
— ^ i ^ B B — n m 
Mq脚 ^trocvtes 4 davs post-confluence 0 8 davs in cultured, phase contraist visible lipht (x7M()) 
j i i m ^ 
Mouse astrocytes 4 davs post-confluence HS dav5g m culture�aft^ 
staining, phase contrast UV rx25Q；) 
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I I ^ W E I 
Mouse astrocytes 10 davs post-confluence ^24 davs in cultured, phase contrast, 
visible light rxlQQ-^  
Mouse astrocytes 10 davs post-confluence (24 days m culture�after GFAP 
staining, phase contrast. UV rxlQO^ 
Page 55 
Chavter 6: General MatPrinh and Mpthn4, 
m^km 
pM 梦? f e S(必 x ! . , 
. . m m M M k M . ^ 
asfrocytps 10 davs pmt-rmifluence (24 dav« in cM\tnre\ phase contr^t, 
v i s i b l e h ^ h f ( V ， 
t mm 
Mouse astrocytes 10 davs post-confluence (24 davs in culture) after GFAP 
staiTiiny, phase contrasr. UV (x250^ 
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63 Culture of human astrocytoma cells -
Human astrocytoma cells (U373 MG) were purchased from a 
commercial source. Cells were removed from liquid nitrogen and 
thawed in 37 T water bath. They were then seeded onto a flask and 
cultured with 10% serum supplemented MEM. Astrocytoma cells were 
then subcultured for another two to four passages before they were 
finally cultured onto 35-mm-diameter dishes. The cells were ready for 
experiments after about one week of culture with the same medium. No 
dibutyryl cyclic AMP (dbcAMP) was added to the medium during 
culture. Mature astrocytoma cells were without processes and had a 
type I astrocyte morphology. 
6.4 Protein Determination 
Protein content of the cells were determined according to the method 
ofLowry et al. (1951). Details of the assay are as follows: 
Lowry reagents: solution A: CUSO4 (l%w/v) + sodium potassium 
tartrate (1% w/v) + Na2C03 (20g/l) in 
NaOH (4g/l) in a ratio of 1:1:100 
solution B: Folin and Ciocalteu's phenol reagent 
a. 0.5 ml of neutralized samples were pipetted into plasticRIA tubes 
b. Suitable protein standards were prepared using BSA (0.1% w/v) 
c. To each tube 1 ml of solution A was added and the mixture was 
allowed to react for 15 to 20 mins 
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for 30 mins • 
e. The protein content was then determined as the absorbance at 750nM 
in a photometer. 
6*5 Gamma � counting 
The amount of radioactivity of the ^^^I-radiolabeled ligands 
binding was determined in a Packard gamma counter (Model 
I 
AutoGanma 5650). The counting efficiency of the counter is 
approximately 74%. The lower energy limit is 15nM and the upper 
limit is 80nM. The background count was determined with water or 
empty RIA tube and it is less than 100 cpm, 
6.6 Beta (P) counting 
Radioactivity of 3h labels and 86处+ was determined in a 
Beckman liquid scintillation counter (Model LS 3801) with a counting 
efficiency of about 50%. The energy range for ^H is from 0 UL to 400 
UL. The background count was determined with scintillation fluid 
alone and was about 40-80 cpm. The amount of radioactivity of tritiated 
chemicals was determined as the count per minute in the presence of 
scmtillation fluid. The amount of radioactivity due to 86Rb+ was 
measured as radiation in the range from lOOUL to 450UL in the 
absence of scintillant (Cerenkov radiation). The background count for 
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7. Receptor Identification and Characterisation -
T.llntroductioii 
Several methods have been used to assess the presence of peptide 
receptors on astrocytes. The mostly widely used approach has been to 
determine the presence of peptide binding sites directly, using 
radiolabeled ligands. Using radioiodinated natriuretic peptides, it is 
possible to identify specific membrane receptors. 
In most target tissues, binding of iodinated ANP (125i-anP) is 
concentration and time dependent, and saturable. Scatchard analysis of 
binding data reveals a single class of high affinity receptor with a 
dissociation constant (K^) in the nanomolar range and a maximal 
binding capacity (Bmax) ranging from 7000 binding sites per cell in 
brain micro vessel endothelial cells (Whitson et al” 1991) to over 
100,000 sites per cell in vascular smooth muscle cells (Hirata et al.， 
1985). Similar results have been observed using 125i_pBNP as a ligand. 
In bovine adrenal cortex (Hashiguchi et al., 1988) and rat trachea cells 
(James and Burastock, 1991), the pattern of distribution of 125i_pBNP 
binding sites is very similar to that of ^^^I-hANP and the specific 
binding sites for 125i-pBNP can be displaced by unlabelled a-hANP 
and pBNP with very similar IC50 values. Scatchard analysis of 125i-
pBNP specific binding also gives linear plots，suggesting the presence 
of a single type of high affinity receptor. These data suggest that pBNP 
and hANP share the same receptor. 
However, truncated and ring-deleted analogues of AN?, such as 
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CANP(4-23) which is devoid of biological activity, are also found to -
bind to target cells with almost identical affinity (Almeida et aL, 1989). 
This suggests the presence of at least two different populations of high 
affinity receptors one of which is linked to subsequent ftmction，and 
one which is not. Covalent cross-linking experiments (Leitman et aL, 
1986) indicate the presence of two receptors. A ISOkDa receptor which 
is associated with biological activity and a 66kDa receptor whose role 
remains unclear (see 9.3.4, p. 156 for further discussion). 
Rat glioma cells and rodent astrocyte cultures have been 
demonstrated to exhibit cGMP production following ANP stimulation 
(Friedl et aL, 1985). Subsequently, specific receptors coupled to cGMP 
production were also identified in a human astrocytoma cell line (Lyall 
et al., 1988). When rat neuronal and astroglial cultures were studied 
together, it was found that the astrocytes contain approximately twice 
the number of ANP receptors, as measured bv 1251-anp specific 
binding when compared to neuronal cultures (Sunmers and T如 g， 
1992). 
This issue was addressed further in the following experiments 
which aimed first to identify natriuretic peptides receptors, and then to 
elucidate binding characteristics in the primary cultures of mouse 
astrocytes. lodinated a-hANP, rANP and pBNP were used in these 
studies which will now be described in detail. 
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12 Materials and Method . 
12.1 Materials 
a-hANF(i.28> rANP(i-28) and pBNP were purchased from the 
sources described earlier (see p.43 for sources of chemicals). 125i (in 
the form of Nal25i，with a specific activity of 17.1mCi/mg) was 
purchased from Amersham International (UK). 
122 Method 
1.12A. lodination of Natriuretic Peptides 
Reagents: - lodogen (lOD) coated onto tubes (lOOnmole/ml in 
chloroform) 
-ice-cold PBS 0.2M, pH 7.5 
(radioactive concentration of 102mCi/nil) 
- pBNP, rANP(i-28) a-hANP(l-28) (stock conc = 
Img/ml) 
Procedure 
a. lOD was mixed 
with 65^1 PBS and 15^1 Na[125i] at room 
temperature 
b. The mixture was allowed to react for 1 min 
c. At the end of 1 min, 20|xl of cold hormone stock solution was added 
to the mixture 
d. The reaction was allowed to continued for a fiirther 20 mins for 
pBNP and 8 mins for a-hANP(i.28) and rANP(i_28) at room 
temperature Page 61 
I 
i. 
Qhapt^ 7; H^c^ptQr Identification 
e. The mixture was then carefully pipetted into an ice-cold tube to . 
stop the reaction 
f. Monoiodinated pBNP was separated with HPLC using the following 
conditions: 
Eluting buffer: A - 5SmM phosphate buffer pH 2.9 
B - 60% ACN in solvent A 
Eluting gradient: 35-55% B, flow duration 45 mins 
Detection wavelength: 215mn (UV) 
g. 10叫 of each fraction was counted for radioactivity in a Packard 
gamma counter (Model AutoGamma 5650) to determine the purity 
of the product 
h. The two fractions with the highest counts were pooled and stored at 
-20OC for subsequent experiments 
122m. Saturable binding of labelled natriuretic peptides 
Reagents: - binding buffer (lOmM HEPES in serum-free MEM 
containing 1% w/v BSA，pH 7.4) 
-iodinated natriuretic peptides (prepared according to the 
method described above) 
_ unlabelled peptides (stock concentration = Img/ml) were 
diluted with binding buffer to IjiiM 
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Background to the method . 
The mefliod for studying saturable binding of a ligand relies on 
the principle that a ligand will bind reversibly and stereospecifically to 
a receptor in a stoichiometric and concentration dependent maimer, 
obeying die law of mass action. Receptor will be saturably bound by 
ligand under equilibrium conditions. Binding of ligand to non-receptor 
sites (non-specific binding) is determined in the presence of excess 
unlabelled ligand. Thus, the study of saturation binding requires that 
labelled ligand is not present in excess. The saturation binding curve for 
specific ligand binding (total binding minus non-specific binding) 
analyzed according to the method of Scatchard (1949) gives an estimate 
of the affinity of the ligand (K^) and an extrapolated determination of 
the maximum number of binding sites (Bmax). In Scatchard analysis, 
the ratio of bound and free (unbound) is plotted against the 
concentration of occupied binding sites (bound). Assuming that the 
interaction between ligand and receptor obeys the law of mass action, a 
linear relationship between the ratio bound/free and bound exists and 
can be expressed by the equation: 
Bound = - K^ (Bound/Free) + Bmax 
Thus, the affinity (Kd) and maximum number of binding sites 
(Bjnax) can be determined experimentally by measuring the amount of 
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Procedure 
a. Astrocytes cultured in monolayer were used for all binding 
experiments 
b. Astrocytes were washed twice with 1ml binding buffer 
c. Astrocytes were equilibrated in binding buffer for 30-60 mins 
d. Total binding was determined by incubating astrocytes with 1 ml 
buffer containing different quantities of radioligand 
e. Non-specific binding was determined by incubating the cell with 
identical media with excess imlabelled natriuretic peptides (l^M) 
f. The cells were incubated with the media for 90 mins 
g. At the end of the incubation, the cells were washed twice with 1 ml 
ice-cold PBS 
h. They were then solubilized with 0.5N NaOH overnight at room 
temperature 
i. The amount of radioactivity in one fraction of NaOH lysate was 
determined in a Packard y- counter 
j. The protein content of another fraction was measured according to 
the method of Lowry (1951) as described on p.57 
122,m. Competitive binding studies 
Procedure 
a. Monolayer astrocytes cultured on 35-mm-diameter culture dishes 
were used. 
b. They were washed twice with binding buffer 
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c. The cells were equilibrated with the same buffer for 30-60 mins . 
i 125i.pBNP, 125i.hANP or 125i-rANP(i_28) at a concentration of 
about 20x105 cpm/ml was added to each dish together with 
increasing concentrations of unlabelled peptides in a final volume 
of 1ml 
e. The mixture was incubated for 90 mins 
f. At the end of the incubation, reaction mixture was aspirated by 
water suction 
g. The cells were then washed three times with 1 ml ice-cold PBS to 
remove any unbound radioligand 
h. The cells were allowed to air-dry for 10 mins 
i. They were then solubilized with 0.5N NaOH overnight at room 
temperature 
j. Radioactivity and protein content were determined as described 
earlier 
Page 65 
Chapter 7: Recpptor Ident{iicatinn 
73 Result 
Specific binding of 125i.hANP and 125i_pBNP to mouse 
astrocytes are both found to increase with increasing concentrations of 
radiolabelled ligand (Fig.7.1 & 7.2). Tables 7.1 and 7.2 simimarise the 
results of two saturable binding experiments with 125i.jiANP and l^Sj. 
pBNP. Scatchard plots derived from analysis of the saturable binding 
data of both radioligands yield straight lines (Fig. 7.3 & 7.4) which 
indicate the presence of either a single class of binding sites or a 
heterogenous class of binding sites with close affinity. Calculation of 
dissociation constant revealed very similar IQj values (0.28 nM for 
125i-hANP and 024 nM for l^Sj.pBNP). The maximal binding 
capacity of specific binding sites for ^^Sj.hANP is 90 finol/mg protein 
(fig. 7.4) in one experiment and 85 fmol/mg protein (Scatchard plot not 
shown), and that for ^^^l-pBNP is 42 fmol/mg protein (fig.7.3) and 78 
fmol/mg protein (Scatchard plot not shown). 
Tables 7.3，7.4 and 7.5 summarise the competitive binding 
results of different radioligands with various unlabeled natriuretic 
peptides. Representration displacement curves are shown in figure 7.5, 
7.6, and 7.7. The half inhibitory concentrations are from 022nM to 
0.25nM for hANP, 0.32nM to 0.44nM for pBNP, and 0.44nM to 0.6nM 
for rANP(i-28). Therefore, the rank order with the three radioligands is 
a-hANP > pBNP > rANP(i-28) but the differences are not statistically 
significant. 
Finally, figure 7.8 shows the effect of incubation with forskolin 
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on self-displacement of 125i_pBNp in mouse astrocytes grown without 
dbcAMP. The pattern of displacement is essentially the same for both 
groups. The IC50 values for them are 02nM. However, the group 
treated with forskolin exhibits greater binding. The maximal binding 
approximately double that of the control. 
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Table 1 • Summary of saturable binding of 1251-pBNP to mouse astrocytes. Results are expressed as mean + SD. 
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Table 7.3. Results of displacement of 125i_hANP binding by various 
natriuretic peptides in mouse astrocytes. Values are expressed as the' 
percentage of bound/total bound (% B/Bo). 
Natriuretic Cone of Experiment I Experiment 11 Experiment Mean 土 SEM 
peptides peptides n=2 n=2 m 一 
n ^ 
Total Count 220000 cpm 204000 c p m 2 1 5 0 0 0 cpm 
Total Binding 11.4% of 12.8% of 11.8% of 
total count total count total count 
Non-specific 9.6% of total 7.7% of total 8.8% of total 
binding binding binding binding 
h A N P T o "O T i 2.33 ± 0 . 6 ~ 
3.3nM 17.5 1.4 12 10 土 1.2 
InM 20.9 9.7 19.7 16.7 土 2.2 
0.33nM 51.5 30.6 37.8 40 土 1.8 
O.lnM 53 68 68.9 63.3一土 3.3 
0.033nM 88.5 74.7 93.9 85.7 ± 4 
lANP 门-28) lOnM 4.85 ±.1.2 
3.3nM 10.4 3.6 7 土 1.9 
InM 20.5 27.8 2 4 ^ 土 2.1 
0.33nM 37 63 50 土 
O.lnM 65.6 92.7 79.^" 土 7.8 
0.033nM 89.9 106.4 98.15一土 4.8 
pBNP l O i ^ KE L2 0 2.56 ± 1 . 2 ~ 
3.3nM 9.8 3.0 7.5 6.77 土 1.2 
InM 22.4 16.8 11 16.7 土 2.1 
0.33nM 62.6 28.1 53.8 48.2 ^ 6.5 
O.lnM 92.6 69.4 85.9 82.6 ± 4.7 
0.033nM 106.2 92.6 91.7 96.8 土 3.2 
Page 70 
Chapter 7. Ppr^fnr f(fent^iicntinn 
Table 7.4. Summary of results of displacement of 125i-pBNP binding 
by various natriuretic peptides in mouse astrocytes.Values are 
expressed as percentage of bound / total binding (% B/Bo). 
Natriuretic Cone of I Experiment I Experimeiitn Experiment |Mean 土 SEM peptides peptides if=2 if=2 m 一 
jr=2 
Total Count 200000 195000 230000 “ 
(cpm) 5.5% of total 6.7% of total 4.9% of total 
Total Binding count count count 
N<m-specific 20.3% of 14.9% of 18.8% of 
binding total binding total binding total binding 
bANP lOnM 13 0 T3 2.93 ± 1 . 4 ~ 
3.3nM 4.2 2.9 13 6:7 ± 2:0 
InM 17.8 8.6 35.9 20.7 土 5.1 
0.33nM 24.9 46.3 66.2 45.8 土 7.5 
O.lnM 55.9 58.8 75.1 63.3 土 3.8 
0.033nM 88.3 90.3 88.1 88.9 土 0.5 
lANTV 丨力 s � lOnM 1 2 5 2 
3‘3nM 7.4 7.4 
INM 19.3 19.3 
0.33NM 4 4 44 
O.lnM 74.9 74.9 
0.03311M 78.7 78.7 
pBNP IOdM ^ Id n 4.36 ± 0.9 
3.3nM 8.2 22.4 1.8 10.8 土 3.8 
InM 26.7 44.5 7.0 26.1 土 6.8 
033nM 38.4 75.9 49.1 54.4 土 7.1 
O.lnM 82 93.1 60.4 78.5 土 6.1 
0.033nM 61.1 101 101 87.7 土 8.4 
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Table 7.5. Summary of result of displacement of 125I-rANP(l-28) by 
various natriuretic peptides in mouse astrocytes. • 
Natriuretic Peptide Cone of Peptides Mean 土 SD • ^ 
a-hANP lOnM 82 ±1.45 
3.3nM \1J±2J 
InM 242 土 6.4 
0.33nM 31.5 ±10 
O.lnM 55.8 ±8.35 
0.033nM 101.5 ±7.5 
rANP(l-28) lOnM 8.5 ± 0 2 
3.3nM 142 ±3.2 
InM 30.3 土 8.5 
0.33nM 65.5 ±18 
O.lnM 78.6 ±4.8 
0.033nM 88.1 ±21 
pBNP lOnM 10.6 ±0.1 
3.3nM 202 ±7.9 
InM 24.1 ±4.5 
0.33nM 61.4 ±5.6 
O.lnM 59.7 ± 8 
0.033nM 102 ±10.1 
Total count = 280,000 cpm per tube 
Total binding = 7.9 % of total count 
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\ 。hANP IC50 = 0.22nM 
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Fig. 7.5 Displacement of ^^^l-hANP by various natriuretic 
peptides in mouse astrocytes. Results are means of 
means of 3 separate experiments (Table 7.3), each 
experiment performed in duplicate. 
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1 2 0 — 
\ \ \ 。hANP IC50 = 0.22nM 80 - \ \ \ 
\ Y 0 rANP IC50 = 0.6nM 
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Fig. 7.6 Displacement of ^^^l-rANP by various natriuretic 
peptides in mouse astrocytes. Results are means from a 
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Log [BNP] (nM) 
Figure 7.8 Effect of incubating astrocytes with 20/iM forskolin 
for 24 hours on displacement pBNP from ^^si.pBNP in astrocytes 
grown without the addition of dbcAMR The IC50 in both groups 
are approximately 0.2nM. 
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7.4 Discussion 
The results indicate that specific binding sites for ANP and BNP -
are present in asfrocytes. The binding characteristics of pBNP to 
astrocytes are similar to those in adrenal cortex with a K^ of 023 nM 
and Bjuax of 36.7 fmol/mg protein (Hashiguchi et al., 1988; Higuchi et 
al” 1989). The binding characteristics of ANP are comparable to otiier 
studies with rat astrocytes with a Kd of O.lTnM and Bmax of 
125fmol/mg protein (Beaumont and Tan, 1990) in one study and a K^ 
of 0.11 nM and Bmax of 78.1 finol/mg protein in another (Sumners and 
Tang, 1992). The similarity of dissociation constants (Kd) for pBNP 
(025nM) and a-hANP (027nM) and IC50 values for various 
radiolabeled natriuretic peptides suggest that the two peptides bind to 
the same receptor. Although the Bmax 如 pBNP (from 42 to 78 
finol/mg protein) appears smaller than that a-hANP (from 85 to 90 
fmol/mg protein), the difference is not statistically significant. There is 
much data to suggest that pBNP exerts biological effects in flie cells via 
a receptor which is shared with hANP. Examples also include bovine 
adrenal (Hashiguchi et al” 1988; Higuchi et al” 1989), and rat trachea 
(James and Bumstock, 1991). More evidence to support this hypothesis 
of a shared receptor is provided in the next chapter which addresses the 
issue of second messenger systems. 
A single class of receptor is suggested by Scatchard analysis. 
However, the results are unable to differentiate receptor subpopulations 
with closely similar affinities. As with other target cells such as smooth 
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muscle cells, the overwhelming majority of receptors in astrocytes may -
be the 66kDa or the ANP-C receptor. The density of the 66kDa receptor 
in astrocytes is similar to those described for smooth muscle cells or 
adrenal cell membranes (Higuchi et al., 1989). This receptor exhibits 
the same affinity as the ISOkDa receptor and it does not distinguish 
between ANP and BNP. Thus, one would not expect Scatchard analysis 
to distinguish these two receptor subtypes. As the 66kDa receptor is not 
very sensitive to changes in natriuretic peptide structure, 125i-rANP， 
125i.hANP and ^25i.pBNP binding would be expected to be similar 
and they would be displaced by other structurally similar natriuretic 
peptides such as a-hANP and rANP with similar potency. 
The expression of high densities of the ANP-C receptor in 
astrocytes may be influenced by cell culture conditions such as 
exposure to serum, or dbcAMP which is used to induce differentiation. 
As shown in figure 7.8, preincubation with forskolin, a compound 
which increases intracellular cAMP by direct stimulation of adenylate 
cyclase thereby exerting a similar effect to dbcAMP, causes an increase 
in maximum binding without altering the IC50 in asti-ocytes grown in 
medium without dbcAMP. This indicates that the affinity of pBNP 
receptors remains unchanged while the number is increased. The 
significance of this remains unclear. It is possible that increase in the 
number of natriuretic peptide receptors is a natural process of astrocyte 
maturation and differentiation in vivo. In this respect, incubation with 
forskolin has been shown to mimic the effect of dbcAMP and induces 
differentiation in astrocytes. 
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8. Second Messenger Systems • 
8.1 Introduction 
A relation between natriuretic peptide receptors, guanylate cyclase 
and cGMP is suggested by the observation that binding of natriuretic 
peptides increases cGMP levels in cells expressing natriuretic peptide 
receptors (Leitman et al” 1986). They have also been demonstrated to 
activate particulate guanylate cyclase in plasma membrane preparations 
from several tissues including rat kidney, adrenal and lung (Waldman et 
al., 1984; Waldman et al.，1985). The activation is specific for the 
particulate isozyme and is concentration dependent (Waldman et al” 
1984), and appears also to be specific to the ISOkDa receptor for 
natriuretic peptides. Detail studies of tiie purification, structure and 
function of particulate guanylate cyclase and natriuretic peptide 
receptors indicate that both guanylate cyclase and natriuretic peptide 
binding activities are contained on a single transmembrane ISOkDa 
glycoprotein (Kuno et aL, 1986). It is the occupancy of the ISOkDa, not 
the 66kDa, receptor which increases intracellular cGMP levels (Kuno et 
al.，1986; Takayangi et al., 1987). It has been proposed that biological 
actions are triggered by the binding of peptide to this ISOkDa receptor 
followed by specific activation of particulate guanylate cyclase and on 
increase in intracellular cGMP. This cyclic nucleotide then mediates the 
biological response of the target cell by stimulating specific protein 
kinases which alter the phosphorylation state of specific proteins or by 
direct actions on ion channels or transporters (O'Donnell and Owen, 
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1989). 
The non-cyclase linked receptor was originally thought to ftmction 
solely as a silent receptor, buffering the circulating ANP (Maack et al., 
1987). However, as described earler (see review on second messenger 
of natriuretic peptides in 5.5, p. 26)，a number of studies now suggest 
that this receptor is involved in signalling and can mediate an inhibition 
of adenylate cyclase and an activation of phospholipase C in response 
to ANP binding (Anand-Srivastava et al.，1986; Hirata et al., 1989). 
ANP has been shown to produce 50% inhibition of agonist (such as 
isoproterenol and forskolin) induced stimulation of adenylate cyclase 
activity in cultured rat mesenteric smoofli muscle cells (Anand-
Srivastava et al” 1984). ANP inhibits both forskolin and sodium 
fluoride stimulated adenylate cyclase activity and it may also alter the 
interaction of GTP-binding proteins with the catalytic site of adenylate 
cyclase (Leitman and Murad, 1987). 
Specific ANP receptors and accumulation of intracellular cGMP 
following receptor binding have recently been demonstrated in rat 
astrocytes (Simoimet et al” 1989). Similar observations have been made 
by our group in mouse astrocytes using both ANP and BNP (Yeung et 
al.，1991). 
The following chapter examines the second messenger system of 
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i . Materials and Method 
8丄1 Chemicals 
a-hANF(1.28) and pBNP were purchased from the source as 
mentioned previously. Human astrocytoma cell line (U373MG, passage 
180) was purchased from American Type Culture Collection (USA) and 
prepared according to the method described in 6.3 on p.57. 3-Isobutyl-
l-methylxanthine (DBMX) was obtained (U.S.A.). cGMP and cAMP 
radioimmimoassay kits were from Amersham International (U.K.). 
Effect of natriuretic peptides on cGMP production 
Reagents: • reaction buffer (lOmM HEPES, 0.5mM IBMX and 1% 
BSA in MEM, pH 7.3) 
-various concentrations of peptides were prepared in reaction 
buffer shortly before use 
-ice-cold isotonic PBS (pH 7.4) 
-ice-cold TCA (6% w/v) “ 
-diethyl ether (water-saturated) 
-0.5NNaOH 
S22.i Time course of cGMP production stimulated by natriuretic 
peptides 
Procedure 
a. Monolayer astrocytes (approximately two weeks after confluence) 
were used 
b. Cells were washed twice with 1 ml reaction buffer 
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c. They were then equilibrated with reaction buffer for 10- 20 mins ' 
d. Astrocytes were then challenged with 1ml IfiM natriuretic peptide 
t . 
I for time period ranging from 1 min to 90 mins 
e. At the end of each incubation period, the reaction mixture was 
aspirated by water suction 
f. The cells were then washed twice with 1 ml ice-cold PBS to remove 
the remaining peptide 
g. 1 ml of ice-cold TCA was added to each dish to stop the reaction 
cGMP extraction 
a. The dishes were frozen at -TO^C for 1 hour 
b. The cells then allowed to diaw at room temperature 
c. The TCA extractable material was then transferred to a RIA tube 
and centrifiiged for 10 min at 3000 rpm, 4' C 
d. The supernatant was then transferred to a glass tube and the pellet 
was discarded 
e. TCA in the supernatant was extracted four times with 2ml water-
saturated ether 
f. The aqueous layer was preserved and freeze-dried overnight 
g. Cell debris was dissolved widi 0.5N NaOH for protein 
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cGMP assay ‘ 
Reagents 
The freeze-dried TCA extracted samples were assayed for cGMP 
using the Amersham cGMP RIA kit which contains assay buffer 
(50mM Tris-HCl and 4mM EDTA, pH 7.5), cGMP standard, [3h]-
cGMP (with a specific activity of 0.02mCi/pmol), (NH4)2S04 (60% 
saturated), cGMP antiserum and blank reagent. 
Principle of method 
The methodology of the cGMP assay followed that outlined with the 
Amersham kit. Briefly, the assay is based on the competition between 
unlabelled cGMP and a fixed quantity of the tritium labelled compound 
for binding to an antiserum which has a high specificity and affinity for 
cGMP. The amount of cGMP in the sample is inversely related to the 
amount of radioactivity bound to antibody. 
Separation of the antibody-bound cGMP from the unbound 
nucleotide is achieved by ammonium sulphate precipitation, followed 
by centrifugation. The precipitate is then dissolved in water and its 
radioactivity determined by liquid B-scintillation counting. The 
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Assay Protocol * 
Tube No [^ HJcGMP Buffer Standard Unkown Blank Antiserum Dose of 
— standard 
JO 60 - _： - 30 zero dose 
^ 30 - 60 - - 30 0.5 卿 1 
5，6 30 ： 60 - - 30 liHnol 
7，8 30 60 - - 30 2pmol 
9,10 30 - 60 ： JO 4pmol 
1 U 2 30 - 60 - - 30 Spmol 
13,14 30 ： ： ： 60 30 Blanir 
15,etc I - - 60 I - I 30 samples 
All volumes are measured in microlitre (ml) 
Assay Procedure 
a. Assays tubes were labelled and arranged according to the protocol 
b. To each tube, 30ml of tritiated cGMP was added 
c. Standards were prepared from reagent 4 to the doses as described in 
the protocol 
A 60ml of buffer was added to tube no.l & 2 to determine maximal 
binding (i.e. binding in the absence of unlabelled cGMP) 
e. 60ml of blank reagent was added to tube no.l3 & 14 for the 
determination of assay blank 
f. 60ml of each sample was added to the rest of tubes 
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g. 30ml of cGMP antiserum was added to each assay tube and the 
tubes were capped and vortexed for a few second 
h. The mixture was incubated in an ice bath at 4 � C for one to two 
hours 
i. At the end of the incubation, 1ml ice-cold (NH4)2S04 solution was 
added to each tube to stop the reaction 
j. The tubes were then vortex mixed and allowed to stand for 5 
minutes (timed from the addition of (NH4)2S04 to the last tube) 
k. The tubes were then centrifuged for 5 to 10 minutes at 4 � C and 
lOOOOrpm 
1. The supernatant was decanted and any excess liquid was wiped with 
tissues, taking care not to disturb the precipitate 
m. 200-500ml of distilled water was then added to each tube to dissolve 
the protein precipitate 
n. The tubes were capped and vortex mixed until all the precipitate 
had dissolved 
o. The content was pippetted to scintillation vial and mixed with water 
miscible scintillant for counting 
Calculation of results 
The concentration of cGMP in the samples is calculated by 
constructing a linear calibration curve, as follows: 
Assay Blank (B) = the count of tubes no. 13 & 14 
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Total binding (Cmax) = the count in the absence of imlabelled • 
cGMP (tube no. 1 & 2) 
Zero-dose binding (Co) = Cmax - B 
Count of standards (Cx) = count in the presence of standards - B 
A plot of Co/Cx against pmol of unlabelled cGMP gives a straight line 
with an intercept of 1 on the ordinate (see standard curve). The linear 
relationship can be expressed in the equation : 
x = m [Co/Cx -1] 
where x is the concentration of cGMP, and m is the slope of the 
straight line. Therefore, the concentration of cGMP in the samples can 
be determined by calculating the Co/Cx values of the samples. 
Protein determination 
a. 200gl of the NaOH lysate was neutralized with 0.5N HCl 
b. Protein content was then determined according to the method of 
Lowry etal. (1951) 
8.2.2.ii. Effept Qf cHffgir印t QPTHpentr^ tipng of n^tnwgtjQ peptides on 
cGMP production in mouse astrocytes and human astrocvtoroa cells 
Procedure 
a. Astrocytes (about 2 weeks after confluence) and human astrocytoma 
(about 1 weeks after subculture) cells grown on 35-mm-diameter 
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b. Cells were washed twice witib 1 ml reaction buffer • 
c. They were then equilibrated with reaction buffer for 10- 20 mins 
d. They were then challenged with 1ml natriuretic peptide at various 
concentrations for 10 mins. The final concentrations used were 
InMto lOmM. 
e. At the end of incubation period, the reaction mixture was aspirated 
by water suction 
f. The cells were washed twice with 1 ml ice-cold PBS to remove any 
remaining peptide 
g. 1 ml of ice-cold TCA was added to each dish to stop the reaction 
cGMP extraction and assay, and protein determination followed the 
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S23 Effect on adenylate cyclase activity 
8»2.3丄 Effect of ANP op cAMP production and its effect on agonist-
induced cAMP production in mouse astrocytes 
Reagents: • reaction buffer (lOmM HEPES, 0.5mM DBMX and 1% 
BSA in MEM, pH 7.3) 
-various concentrations of peptides were prepared in reaction 
buffer shortly before use 
-ice-cold PBS (pH 7.4) 
-ice-cold TCA (6% w/v) 
-diethyl ether (water-saturated) 
-0.5N NaOH 
Procedure 
a. Astrocytes in monolayers attached to 35mm culture dishes were 
used 
b. The cells were then washed twice with 1 ml reaction buffer 
c. They were then equilibrated with reaction buffer for 10- 20 mins 
d. The cells were then challenged with 1 ml reaction buffer containing 
ANP or other agonists (l^M) for 10 mins 
e. At the end of the incubation period, the reaction mixture was 
aspirated by water suction 
f. The cells were washed twice with 1 ml ice-cold PBS to remove any 
remaining peptides 
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and release in如cellular cAMP ‘ 
cAMP extraction 
TCA was removed using the same procedure as with cGMP, i.e. 
the ether extraction method described previously. The aqueous layer 
containing cAMP was freeze-dried and kept at -70�C before ttie assay. 
c AMP assay 
Reagents 
The freeze-dried samples were assayed for cAMP using an 
Amershain cAMP assay kit which contains assay buffer (50mM Tris-
HCl，4mM EDTA buffer pH 7.5), binding protein (purified from 
bovine muscle), [8-3H]adenosme 3’，5’-cyclic phosphate (with specific 
activity of 0.028 mCi/pmol), adenosine 3,，5’-cyclic phosphate standard, 
and finally charcoal adsorbent. 
Principle of assay 
As with the cGMP assay, this assay is also based on die 
competitive binding between unlabelled cAMP and a fixed quantity of 
tritiated cAMP to a specific binding protein. The amount of labelled 
protein bound cAMP complex is inversely related to the amount of 
unlabelled cAMP present in the assay sample. Measurement of the 
protein-bound radioactivity enables the amount of unlabelled cAMP in 
the sample to be calculated. 
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Separation of the protein bound cAMP from the unbound ' 
nucleotide is achieved by adsorption of the free nucleotide on to coated 
charcoal, followed by centrifugation. An aliquot of the supernatant is 
then removed for liquid scintillation counting. The concentration of 
unlabelled cAMP in the sample is then determined from a linear 
standard curve. 
Assay protocol 
Tube No. Buffer Standard Samples [%]cAMP Binding 
protein 
： ： 30 ： Charcoal Blank 
- M JO ： J： J O 60 Zero dose 
： 30 ： 30 60 Ipmol 
J A : 30 ： 30 60 2 卿 1 
9,10 30 ： 30 ^ 4pmol 
11，12 - 30 ： JO _60 Spmol 
. 13,14 - 30 ： 30 60 16pmol 
15’etc I - I 30 30 30 60 unkpown 
All volumes are measured in microlitre Qil) 
Assay procedure 
a. Assay tubes were labelled and arranged according to the protocol 
b. 90ul of buffer was added to tube no.l & 2 for the determination of 
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assay blank -
c. 30ml of buffer was added to tube no.3 & 4 for the determination of 
total binding (binding in the absence of unlabelled cAMP) 
d. The standards were prepared from serial dilution from reagent 
containing the unlabelled cAMP with assay buffer 
e. 30ml of each sample was added to the remaining tubes 
f. To each tube, 30ml [ 3 H ] C A M P was added 
g. 60ml of binding protein was added to each tube except tube no. 1 & 2 
h. The tubes were capped and vortex mixed for a few second 
i. The tubes were then allowed to incubated in an ice bath kept in a 
4 � C cold room for 2 hours 
j • 20ml of ice-cold distilled water was added to the charcoal reagent at 
least 15 minutes before the end of the incubation and the charcoal 
was stirred continuously before use 
k. At the end of the incubation period, 100ml of charcoal suspension 
was added to each tube and the mixture was mixed well 
1. The charcoal was then centrifaged down at 4*C, lOOOrpm 
m. 200ml of supernatant from each tube was removed to scintillation 
vials and mixed with water miscible scintillant for the 
determination of radioactivity 
Calculation of results 
The method of calculation of results is similar to that of cGMP 
determination. A plot of the ratio of total count (Co) and the count in 
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the presence of sample (Cx) against the concentration of unlabelled 
cAMP would yield a straight line and can be expressed by the equation, 
x=m[Co/Cx-l] 
Thus, the concentrations of unlabelled cAMP in the samples can be read 
from the Co/Cx values from the standard curve. 
Protein Determination 
The cell debris was solubilised with NaOH. Protein content of the 
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83 Results -
Effect of natriuretic peptides on cGMP Production 
The results demonstrate thai a-hANP and pBNP stimulate 
infracellular cGMP production in a time- and dose-dependent manner. 
cGMP production peaks between 5 to 10 min in response to both hANP 
and pBNP as depicted in Fig. 8丄 Hence, 10 minutes was chosen for 
dose response studies. The dose response curves of a-hANP and pBNP 
are similar with a half maximally stimulatory concentration (EC50) at 
approximately lOOnM (Fig. 8.3). In both cases, cGMP production 
plateaues at a maximal concentration of IjjM. However, the magnitude 
of the effect of pBNP on cGMP production is greater than that of a -
hANP. pBNP elevates cGMP content from a basal level of 2.73 土 0.39 
pmol/mg protein to a maximal level of 19.06 土 ：3»2 pmol/mg protein, 
whereas a-hANP at maximal stimulatory concentration (l^M) 
stimulates cGMP production to a level of 6.75 土 0.38 pmol/mg protein. 
Figure 8.4 demonstrates that a-hANP and pBNP can also 
stimulate cGMP production in human astrocytoma cells (U373 MG). 
The half maximal (EC50) and maximal stimulatory concentrations for 
a-hANP and pBNP are also approximately lOOnM and l|iM 
respectively. However, compared to astrocytes, the magnitude of the 
effect was smaller for both peptides. cGMP level is stimulated from a 
basal level of 1.76 土 0.1 pmol/mg protein to maximal levels of 6.82 土 
0.13 pmol/mg protein for pBNP and 2.65 土 0.1 for a-hANP at a 
concentration of IjiM. When both peptides are incubated with 
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astrocytes at flie same time, no additive or synergistic effect is observed ‘ 
(Fig. 8.5 & 8.6). As shown in figure 8.5，at low concentrations of 
pBNP, cGMP production is slightly increased compared with l^M a -
hANP alone. However, the dose response curve of pBNP is shifted 
downward at higher concentrations of pBNP. cGMP produced in 
response to both peptides in combination is lower than that produced by 
pBNP alone. cGMP levels decrease from a value stimulated by l^M 
pBNP of 10.32 土 1.02pmol/mg protein to 6.58 土 0.55 pmol/mg protein 
when incubated with 1 |xM a-hANP. 
Figure 8.6 shows the dose response curve for a-hANP stimulated 
cGMP production in the absence and presence of lOOnM pBNP. It can 
be seen that with lOOnM pBNP alone the cGMP production is 27.1 
pmol/mg protein. Increasing concentrations of a-hANP cause a 
significant reduction of cGMP production. 
Finally, in figure. 8.7，pBNP is shown to have a greater effect on 
cGMP production in astrocytes grown with dbcAMP compared to tHose 
without. The half-maximal stimulatory concentrations remain similar 
for both types of astrocytes (approximately lOOnM). 
Inhibition of adenylate cyclase 
Fig. 8.8 shows that a-hAMP ( 1 _ does not affect cAMP 
production induced by various stimulants in mouse astrocytes. 
However, when the dose response for forskolin induced cAMP 
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found that, at low concenta^tions of forskolin (InM and lOnM), cAMP • 
production is significantly reduced. There is no difference observed at 
higher concentrations of forskolin. 
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1，- / 
R 二 0.996 ^ ^ 
° i ‘ ！ ： i i i i 1 
2 3 4 5 6 7 8 
cGMP conc (pmole) 
Fig 8.1 A Standard curve for cGMP determination using 
Amersham radioimmunoassay kit. 
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Fig. 8.1 B Standard curve for cAMP determination using 
I Amersham radioimmunoassay kit. 
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2 5 - 1 . 
I 
2 0 -






« 1 0 - /丄 
1 / 
/ ^ 1 -hANP 
T — 1 - ^ 
Control ^ 
0 - 1 — — i — — i — — r — — I — — i — — I — — i — — 1 
0 10'® 10-® 10-7 10-6 1 0-5 
Peptide conc (M) 
Fig 8.3 Dose-response curve for hANP and pBNP on cGMP 
production in mouse astrocytes. Results are means 土 SEM 
of 3 separate experiments, each performed in triplicate. 
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7 -
A 
3 / 丄pBNP 
1 j / I- ^ 
^ C D n t r o l — 
hANP 
1 -
° I i I " H i i I i I 
0 10-9 10-8 10-7 10-6 10-5 
Peptide conc (M) 
Fig 8.4 Dose-response curve for hANP and pBNP induced 
cGMP production in human astrocytoma cells. Results are 
means 土 SEM of 2 separate experiments, each performed in 
triplicate. 
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1 2 - n 
T pBNP 
1 0 - J / alone 
I f 
— 6 - / 1： 丄 IjLiMhANP 
Buffer 2: 
0 1 i i i i 1 1 1 
0 10.® 10-® 10-7 10-® 10-5 pBNP conc (M) Fig. 8.5 Effect of hANP (1/jM} on concentration dependent stimulation of cGMP in mouse astrocytes. The up r line i  he dose response curve for pBNP lone and the lower line is hat in the presence of /jM f hANP. Results are means + SEM of at l ast 4 separate xp rim ts, each with tr plicat  d termina ion . 
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5 0 — 
r /KH\ 
� r \ 
o 2 0 - X _ T T 
H i 1 1 i i i 1 
0 10-9 10-® 10-7 10-6 10-5 
hANP Conc (M) 
Fig. 8.6 Effect of pBNP on hANP-induced cGMP production in mouse 
astrocytes. The lower line is dose-response curve for hANP alone and the 
upper line is the dose-response curve for hANP in the presence of lOOnM 
pBNR Results are means 土 SEM of at least 4 separate experiments, each 
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pBNP conc (M) 
Fig 8.7 Dose response curve for pBNP on cGMP 
production in astrocytes grown in medium supplemented 


















































































































































Fig. 8.8 Effect of different agents 
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P production and the effect of hANP (1;uM
) in 
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1000 -| 
8 0 0 一 
I jr 
^ Forskolin alone / /丄 
^ 600 - 丨 
E 关 Forskolin with hANP / 
I i 4 0 0 -
$ � 
/ I 
200 - z / 
^ ^ ^ ^ ^ ^ ^ * 
o J j i 1 i i — — 
Control 10-9 1〇-8 lO'? lO.a 
Forskolin conc (M) 
Fig. 8.9 Effect of hANP (IjuM) on forskolin-induced cAMP 
production in mouse astrocytes. * indicates a statistically 
significant difference between the two responses. Results 
are means + SEM of 2 separate experiments, each 
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8.4 Discussion 
Effect of natriuretic peptides on cGMP production 
The results confirm that natriuretic peptides stimulate 
intracellular cGMP accumulation. The present findings, taken together 
with the results presented in the previous chapter, indicate the presence 
of natriuretic peptide receptors, coupled to guanylate cyclase, on the 
cell membrane of mouse astrocytes. Although this system is apparently 
more responsive to pBNP than a-hANP in terms of maximal cGMP 
production, the half-maxiraal stimulatory concentrations for both 
peptides are very similar (approximately lOOnM). The difference in 
maximal response is unlikely to be due to species differences as a -
hANP is only one amino acid different from rANP(i-28) whereas the 
structure of pBNP is more divergent (see section on structure of 
natriuretic peptides in 5.3, p.l2). 
The fact that exposure of astrocytes to a-hANP and pBNP 
together did not produce any additive or synergistic effect on cGMP 
production compared to pBNP alone supports the hypothesis that both 
peptides share the same receptor. Furthermore, since a high 
concentration of a-hANP suppresses the pBNP-induced cGMP 
response, it is likely that the two peptides compete for the same effector 
sites, ANP acting as a partial agonist. 
However, there is a discrepancy between binding affinities ( K j 
for a-hANP, 0.27 nM; for pBNP, 0.25 nM) and the concentration 
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approximately lOOnM) which is 2-3 orders of magnitude higher than 
the K^ values. This may imply that a high receptor occupancy is • 
required to elicit the cGMP response. Alternatively, it could be 
explained by the presence of a low affinity guanylate cyclase coupled 
receptor not revealed in the binding studies. It may be preferentially 
activated by pBNP. However, results from the binding studies indicate 
that there is either a single class of high affinity receptor or multiple 
classes all with similar affinities and show no apparent difference 
between the binding characteristics of the two peptides. 
Chang et al., (1989) and Chinkers et al., (1989) have reported 
that there are two subtypes of guanylate cyclase coupled receptor, 
termed ANP-A and ANP-B receptors. ANP-B receptor is most 
responsive to CNP (Roller et al., 1991), followed by BNP whereas ANP 
and BNP are equipotent in cGMP stimulation via flie ANP-A receptor 
(Chang et al.，1989). This is supported by the finding that in tissues 
such as endothelial cells where the predominant form of active receptor 
is ANP-A receptor, hBNP and pBNP are equipotent to a-hANP and 
rANP in cGMP production (Suga et al.，1992). On the other hand, the 
same study has shown that pBNP is more potent than a-hANP in tissues 
such as aortic smooth muscle cells and mesangial cells where ANP-B 
receptor is expressed predominantly. The results with mouse astrocytes 
are similar to the latter, implying that the majority of guanylate cyclase 
coupled receptor is of the ANP-B form. This view is further supported 
by the recent demonstration by our group that C-type natriuretic peptide 
Page 110 
I 
Charter 8: Second Swit隱 
produces an approximately 20-fold greater maximal stimulatory effect ' 
tban a-hANP and BNP (Yeung et al, 1992). Thus, the more selective 
response to pBNP than a-hANP in astrocytes may be explained by the 
predominant expression of the ANP-B receptor. 
The cGMP response to natriuretic peptides in mouse astrocytes is 
affected by the degree of differentiation. DbcAMP is known to induce 
differentiation of astrocytes in culture, with the development of long 
branching processes Puffy, 1983). It changes type I astrocytes into the 
type II process-bearing form by altering the phosphorylation states of 
many cytosolic proteins such as GFAP and vimentin (McCarthy et al” 
1985). It also increases the levels of these two proteins on long term 
exposure (Goldman and Chiu, 1984). The continued presence of 
dbcAMP is required for the maintenance of this morphology. DbcAMP 
also induces a wide range of biochemical changes. These include the 
activation of a number of enzymes, e.g. carbonic anhydrase, Na+-K+-
ATPase, lactate dehydrogenase (Kimelberg et al 1978); and the 
induction of some unidentified proteins (Hansson et al., 1980). Thus, it 
is possible that dbcAMP enhances the expression of natriuretic peptide 
receptors in astrocytes，and this may be a natural maturation process of 
astrocytes. As a result, a more pronounced effect of pBNP is seen in 
astrocytes differentiated with dbcAMP. 
The results indicate that natriuretic peptides are able also to 
stimulate cGMP production in human astrocytoma cells. The maximal 
stimulatory effect of both peptides is much smaller than in mouse 
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astrocytes, although the EC50 values for both cell types are similar . 
(approximately lOOnM). The smaller effect may be explained by either 
a smaller pool of receptors in astrocytoma cells or the presence of low 
affinity guanylate cyclase coupled receptor. The displacement curve of 
125i-hANP by hANP in astrocytoma indicates a low affinity receptor 
(IC50 values ranging from 50 to 500nM) (result not shown). 
Inhibition of adenylate cyclase 
These results suggest that a-hANP inhibits forskolin-stimulated 
cAMP production. Forskolin differs from most 6-adrenergic agonists in 
that it directly stimulates adenylate cyclase and causes cAMP 
production without prior receptor binding. The inhibition by ANP is 
only seen at low concentrations of forskolin. This may be due to ANP 
exerting its inhibitory effect by altering the interaction of OTP-binding 
proteins with the catalytic site of adenylate cyclase. Therefore, at 
maximal stimulatory concentrations of forskolin, the catalytic sites may 
be fully occupied by forskolin molecules, fully stimulating the 
adenylate cyclase system. The lack of effect of ANP on other agonist 
(isoproterenol and VIP) stimulated cAMP production, as shown in Fig. 
8.8, may also be attributed to this. It is unlikely that ANP affects 
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9. Biological Actions of Natriuretic Peptides 
9.1 Potassium Transport 
9.1.1 Introduction 
Most cells have mechanisms to regulate intracellular Na+ and K+ 
concentrations. The sodium-potassium pump is present in the 
membranes of most mammalian cells. It pumps three Na+ ions out of 
and two K+ ions into the cell (for review see Skou, 1988). The transport 
is electrogenic and requires energy. The Na/K pump is a membrane 
bound ATP-hydrolysing enzyme system which converts chemical 
energy from hydrolysis of ATP to an electrochemical gradient of 
cations. It is also known as Na+-K+-ATPase because of its enzymatic 
properties. Na+-K+-ATPase is activated by the combined effect of Na+ 
on the cytoplasmic side and K+ on the extracellular side of the 
membrane, and is inhibited by various glycosides. The most widely 
used has been ouabain (g-strophanthin). It binds to the extracellular side 
of the system and inhibits ATP hydrolysis. The contribution of Na+-
K+-ATPase to K+ uptake can be determined as the ouabain-sensitive 
uptake in the presence of maximally inhibitory concentration of 
ouabain. 
Another mechanism affecting the intracellular K+ concentration is 
the Na/K/Cl cotransport system. This mediates the coupled, electrically 
neutral transport of Na+，K+ and CI" ions across cell membranes. A 1 
Na+: 1 K+: 2 CI" stoichiometric relationship was demonstrated first in 
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tissues including vascular smooth muscle cells and astrocytes. It “ 
appears to serve an important physiological function in the transport of 
salt and water and has a role in the maintenance and regulation of cell 
volume. Reduced levels of Na/K/Cl cotransport in vascular smooth 
muscle cells may contribute to the pathogenesis of essential 
hypertension (ODonnell and Owen, 1988). Cotransport activity is 
inhibited by loop diuretics such as furosemide and bumetanide (5-
sulfamoylbenzoic acid) (Schlatter et al” 1983). The regulation of this 
system at the molecular level is still unclear. Activation requires ATP 
and probably occurs by a protein kinase-catalyzed process (Saier and 
Boyden, 1984). 
In this connection, ANP and cGMP have been shown to 
stimulate the Na/K/Cl cotransporter in vascular smooth muscle cells 
(O'Donnell and Owen, 1986; O'Donnell and Owen, 1988) and 
endothelial cells (Fujita et al” 1989). Stimulation leads to a net decrease 
in intracellular Na+ ions. This decrease could in turn cause a decrease 
in intracellular Ca2+ ions, via the Na/Ca exchange mechanism 
(Blaustein, 1974)), and could explain the vasorelaxant effect of ANP. 
This action of ANP provides a link between its physiological actions 
and cellular response as ANP and Na/K/Cl cotransport both influence 
cell volume regulation and salt and water excretion. However，in 
contrast, another study, using winter flounder intestine, shows that ANP 
inhibits this system (O'Grady et al.，1985). 
In addition to vascular tissues, receptors for natriuretic peptides 
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have been demonstrated in tissues and cells where the function is not ' 
known. These include mouse astrocytes in which specific binding and 
intracellular accumulation of cyclic GMP, have been demonstrated with 
a-hANP, pBNP and C-type natriuretic peptide (Yernig et al., 1991; 
Yeimg et al., 1992) (see also section 5.5, p. 22). 
Despite extracellar migration of K+ ions during neuronal activity, 
the maximal extracellular K+ concentration never exceeds 6-12 mM 
(Heinemann and Lux, 1977). Therefore, mechanisms must exist for 
clearance of extracellular K+ ions. There is now evidence that glial cells 
are active in removing K+ ions (see also Review on Astrocytes, 5.7.3, 
p.34). The mechanism involved may include hormone induced removal 
of K+ in the extracellular medium. Since ANP in some target tissues, 
stimulates potassium transport by activating the loop diuretic-sensitive 
Na/K/Cl cotransport, and regulation of extracellular electrolyte and 
fluid concentration by astrocytes is mediated in part by this 
cotransporter, it is possible that natriuretic peptides may also influOTce 
potassium transport in astrocytes thereby assisting fluid and ionic 
balance in the CNS. 
Experiments have been conducted to examine the K+ transport 
systems in primary cultures of astrocytes, focussing mainly on the Na/K 
pump and Na-K-Cl cotransport system. 86Rb+ was used as a tracer for 
K+ influx as Rb+ and K+ have similar affinities for these pathways 
(Owen and Prastein, 1985). The effects of natriuretic peptides and a 
C G M P analogue (Br-cGMP) on potassium transport in astrocytes have 
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9.12 Materials and Method 
9A2A Materials 
a-hANP(i-28)，pBNP and CNP were from the sources described 
earlier and rANP(5-28) was purchased from Bachem (USA). Br-cGMP, 
ouabain and bumetanide were obtained from Sigma (U.SA.). The 
86Rb+ isotope (in the form of 86RbCl with a specific activity of 1-
8mCi/mg) was purchased from Amersham International (U.K.). 
9.1 丄ii Methods 
Reagents - reaction buffer (HEPES buffer containing 5mM K+)， 
• different concentrations of natriuretic peptides diluted with 
reaction buffer 
-ice-cold isotonic PBS pH 7.4 
-ice-cold TCA (6% w/v) 
-NaOH (0.5N) 
A. Time course of Rb+ uptake 
Procedure 
a. Prior to ion transport measiirement, astrocyte monolayers were 
washed twice witfi reaction buffer. 
b. Cells were equilibrated in this buffer for 5 to 15 mins. 
c. Cells were then preincubated with 1ml buffer containing ouabain 
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d At the end of the preincubation, media were aspirated with water 
suction and replaced with identical fresh media containing 8 6处+ at 
a concentration of about 2x 105 cpm/ml). 
e. The cells were then incubated with 8 6处+ at 37'C or 22*C for 
various time points as indicated in figures 1 and 2. 
f. Uptake was terminated by aspirating the media and washing twice 
with ice-cold PBS (1ml) to remove extracellular Rb+ 
g. The dishes were allowed 10 mins to dry and the cells were then 
solubilized with NaOH. 
h. Intracellular 8 6处+ was determined as the amount of radioactivity 
in the lysate which was measured as Cerenkov radiation in a 
Beckman liquid scintillation counter. 
i. Protein content was determined by the method of Lowry. 
B. Concentration-dependent inhibition of on K+ transport by 
bumetanide 
Procedure 
a. Monolayer astrocytes were washed and equilibrated with reaction 
buffer as described earlier 
b. Cells were preincubated with different concentrations of bumetanide 
together with ImM ouabain for 5 mins at 37 
c. The cells were then incubated with identical fresh media containing 
86Rb+ (about 2x105 cpm/ml) for 10 mins 
d. Uptake was terminated by aspirating the media with water suction 
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and washing with ice cold PBS • 
e. Cells were solubilized with NaOH and the amount of radioactivity 
and protein content were determined using the methods described 
previously. 
f. Results were expressed as a plot of ouabain and bumetanide 
insensitive 6Rb+ uptake (cpm/mg protein) against different 
concentrations of bumetanide. 
C. Effect of increasing extracellular K+ on 86Rb+ uptake 
Procedure 
a. Astrocyte monolayer were washed and equilibrated with reaction 
buffer 
b. For experiments to determine the contribution of ouabain-sensitive 
and bumetanide-sensitive components of K+ uptake under 
conditions of increasing extracellular K+, astrocytes were first 
preincubated with ImM ouabain and lOOuM bumetanide for 5 
minutes. 
c. The cells were then challenged with identical media containing 
different concentrations of K+ which was made by dissolving 
various amounts of potassium gluconate and 86处 in the buffer, 
such that specific radioactivities were kept constant irrespective of 
the concentration of K+. 
d. The cells were incubated with 86Rb+ for 60s at 22* C 




I i i 
Chapter 9: Biological Actions 
ice-cold PBS 
f. Cells were solubilized with NaOH 
g. Radioactivity and protein content were determined as described 
earlier. 
D. Effect of natriuretic peptides on K+ transport 
I. Effect of pBNP on the time course of 86Rb+ uptake 
Procedure 
a. Astrocyte monolayers grown on dish were washed with and 
equilibrated in reaction buffer 
b. The cells were then preincubated with buffer, ouabain (ImM), or 
ouabain (ImM) plus bumetanide (lOOuM) for 5 mins at 22�C 
c. The cells were then incubated with identical fresh media with or 
without lOOnM pBNP for an additional 10 mins 
d. At the end of this incubation, the media were aspirated and replaced 
with fresh media containing 86孙+ at a concentration of 2x1 
cpm/ml 
e. The cells were then incubated with for various times ranging 
from 1 mintoS mins at 37*C and 15 s to 100 s at 22X 
f. Uptake was terminated by the method described above (see p. 117) 
g. Radioactivity and protein content were then determined by the 
methods described earlier. 
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II. Effect of ANP, rANP(5_28)，Br-cGMP and different concentrations 
of pBNP and CNP on Rb+ uptake 
Procedure 
a. Astrocyte monolayers were washed with and equilibrated in the 
reaction buffer 
b. The cells were then preincubated with a-hANP (ImM), rANP(5_28) 
(ImM), Br-cGMP (lOOmM) and various concentration of pBNP 
and CNP at IXC for 10 mins 
c. The cells were then incubated with reaction buffer containing 86处 
at a concentration of 2x 105 cpm/ml 
d. Uptake was terminated after incubating with Rb for 30s. 
e. Radioactivity and protein content were determined using the 
methods described earlier. 
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9.13 Results 
Unidirectional potassium influx 
Figure 9.1.1 depicts the time course of Rb uptake at 37'C in tibe 
presence and absence of the potassium transport inhibitors, ouabain and 
bumetanide. The contribution of the ouabain-sensitive component is 39 
土 1.5% and of the bumetanide-sensitive component is 7.7 土 0.8% of die 
total Rb uptake. The uptake reaches a plateau after approximately 6 
minutes, when studied at 37 C. At a reduced temperature (22'C), Ae 
uptake remains linear up to 100s (Fig. 9.12). The estimated uptake rate 
is nOnmol K+ mg-lmiirl at 22*C. The half maximal inhibitory 
concentration of bumetanide in the presence of ouabain (ImM) on Rb+ 
uptake is approximately 30uM as shown in Fig.9.1.3. 
Rb+ uptake increases with increasing concentrations of 
extracellular K+ spanning the physiological range (5mM to 12.5mM) 
(Fig. 9.1.4) and a higher pathological range (lOmM to 50mM Fig. 
9.1.6). However, the contributions of ouabain-sensitive and 
bumetanide-sensitive Rb+ uptake are not significantly altered when 
astrocytes are incubated wifli either 5mM or 1 OmM K+ (Table 9.1.1). 
Effect of natriuretic peptides 
The time course of Rb+ uptake is not altered in the presence of 
lOOnM pBNP (the half-maximal concentration for cGMP stimulation in 
mouse astrocytes, see 8.3 p. 97) as shown in Fig. 9.1.5. Also, total Rb 
uptake is insensitive to natriuretic peptides (pBNP and CNP) at a range 
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of lOnM to lOOOnM (Table 9.1.2). Other natriuretic peptides and cGMP • 
analogues are also without effect on total Rb uptake (Table 9.1.3). 
Finally, the effect of CNP on the response of astrocytes to increasing 
extracellular K+ concentrations was examined. Again, no statistically 
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Table 9.1.1 . 
Relative contribution of ouabain-sensitive and bumetanide-sensitive Rb 
uptake at physiological K+ concentration (5mM) and elevated K+ 
concentration (lOmM). Results are expressed as mean 土 SEM (cpm/mg 
protein) of a single experiment with 5 dishes for each group. 
5mMK+ 10mMK+ 
Total Rb+ uptake 2245 土 200 3348 土 52 
Ouabain sensitive 645 土 18.3 864 土 27.6 uptake (28.7 %) ^5.8%) 
Bumetanide-sensitive 352 土 10.8 516 ±22.1 uptake (15.6%) (15.^/o) 
Table 9.1.2 
Effect of different concentrations of pBNP and CNP on total Rb uptake 
in mouse astrocytes. Results (cpm/mg protein) are means 土 SEM of two 
separate experiments with triplicate determinations. No statistical 
significance from the control is observed for all the concentrations for 
both peptides. 
Control lOnM lOOnM 500nM lOOOnM 
pBNP 14375±647 16544±1177 15827±878 16030±1079 14553±958 
CNP 3248±267 2933±106 2827±137 3133±107 3588±319 
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Table 9.1.3. 
The effect of various natriuretic analogues and cGMP analogues on 
total Rb+ uptake. None of the test group results differs from the control 
which is incubation with buffer only. Results were expressed as mean 土 
SE of 3 separate experiments, each performed in triplicate. 
Agent Total Rb+ uptake (cpm/mg protein) 
Control 2054 ± 132 
pBNP (IjnM) 2056 ±54 
rANP(5_28) ( W ) 2 3 4 4 土 1 2 9 
a-hANP (l^M) 2171 ±101 
CNP(lOOnM) 2196 ±87 
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Fig 9.1.1 Time course of total Rb+ uptake and uptake in 
the presence of ouabain (1 mM) and bumetanide (0.1 mM) 
in mouse astrocytes at 37°C. Results are means 土 SEM 
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Fig 9.1.2 Time course of total Rb+uptake at 22。C in 
mouse astrocytes. Results are means 土 SEM of 3 
separate experiments, each performed in duplicate. 
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Fig. 9.1.3 Concent ra t ion dependent inhibit ion by bumetanide 
(in the presence of 1 mM ouabain) of Rb+ uptake in mouse 
astrocytes. Cells were pre incubated with dif ferent 
concentrat ions of bumetanide with 1 mM ouabain, and then 
incubated with ®®Rb^for 1 min. Results are means of a single 
exper iment with tr ipl icate determinat ions. 
Page 127 
) • 
Chapter 9: Biolo^cal Actions 
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Fig 9.1.4 Rb+uptake in mouse astrocytes over a physiological range 
of K+(5mM to 12.5mM)- K+concentration was increased by dissioving 
potassium gluconate in MEM. Na+and CT concentrations remain 
constant. The specific radioactivity was kept constant in all 
concentrations of external K+. 
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Fig. 9.1.5 Effect of pBNP (lOOnM) on total Rb+uptake at different 
t ime points in mouse astrocytes. The cells are preincubated with 
HEPES-buffer or pBNP for 10 mins before the incubation with Rb+ 
at 37°C. Results are means 土 SEM of 2 separate experiments, each 
performed in dupl icate. 
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Fig. 9.1.6 Effect of CNP on the response of mouse astrocytes to 
elevated extracellular K+. The cells were first stimulated with lOOnM 
CNP or HEPES-buffer for 10 mins before switching to media with 
different concentrations of K+. The specific activity was kept constant 
in the media. Results are means 土 SEM of 2 separate experiments, 
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9.1.4 Discussion 
Unidirectional potassium transport in mouse astrocytes 
The kinetics of potassium transport in this preparation of mouse 
astrocytes differs from most published reports on astrocytes or other 
cell types. Firstly, K+ transport, measured as Rb+ uptake, is very rapid. 
The uptake becomes non-linear at 60s and reaches saturation within 6 
mins at 37�C. At 22�C the uptake remains linear for up to 100s. The 
initial uptake rate, estimated from figure 9.1.2，is approximately 170-
200 nmol K+mg-lmin-l. These values are in agreement with the high 
K+ uptake reported by Hertz (1978) in mouse astrocytes but are higher 
than those obtained in rat astrocytes (19.6 nmol K+mg-lmiirl) 
(Beaumont and Tan, 1990). The results are, however, lower than those 
demonstrated by Walz and Kimelberg (1985) in mouse astrocytes 
(approximately 2000 mnol K+ mg-1 min" )^. The difference may be 
explained by the fact that Walz and Kimelberg (1985) conducted all 
transport studies at 3TC with as a tracer for K+ transport instead 
of 86Rb+，while the values here are calculated from experiments done 
at 22'C. Also, the uptake rate in studies by Walz and Kimelberg was 
estimated from the first 10s of uptake while the values here are from the 
regression line of four time points spanning the first minute of uptake. 
In contrast, the uptake is more rapid than in rat astrocytes in 
which linear uptake is maintained at 37�C for 15 mins (Tas et al” 1987) 
to 30 mins (Beaumont and Tan, 1990). 
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small contribution from bumetanide-sensitive uptake, which is less than • 
10% of the total in the present study. This component has been shown 
to range from 33% (Tas et al.，1987) to 50% (Walz and Kimelberg, 
1985) in rat astrocytes. These results could suggest a real species 
difference. However，they may also be attributed to differences in 
culture conditions as the rat astrocytes used by Beaumont and Tan 
(1990) were mostly type 1 astrocytes displaying flattened morphology 
while mouse astrocytes in the present study were differentiated into 
process-bearing form with dbcAMP. The findings of Walz and 
Kimelberg (1985) that dbcAMP treatment induced an increase in K+ 
accumulation in rat but not in mouse astrocytes provide support for 
both hypotheses. 
Over 50% of the total uptake is ouabain and bumetanide 
insensitive. This may be due to the presence of extensive K+ channel 
systems in mouse astrocytes. This is compatible to the high K+ 
conductance of cat glial cells in vivo (Trachtenberg and Pollen, 1970). 
In this connection, Sonnhof and Schachner (1984) found at least 3 
different K+ channels in cultured mouse astrocytes. It is uncertain 
whether this is an effect of culture conditions or reflects complex K+ 
channel mechanisms in vivo. In addition, the fact that increasing the 
extracellular K+ to lOmM causes an increase in uptake without altering 
the contribution of either ouabain-sensitive or bumetanide-sensitive 
component (Table 9.1.1) indicates that the increased uptake is due to 
passive Donnan forces. This ouabain and bumetanide resistant uptake 
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i-
can be inhibited by BaCl2 which blocks the passive K"channels (Walz -
et al.，1984). Therefore, it is likely that the ouabain- and bumetanide-
resistant uptake is due to passive movement of K+ through potassium 
channels. 
Although die bumetanide-sensitive component is small, 
bumetanide can still induce a concentration dependent inhibition on 
Rb+ uptake, with a half maximal inhibitory concentration of SOpM. 
Studies of binding of [3H]bumetanide to a variety of tissues reveal a 
range of affinities (expressed as IC50) from 5x10" llM in apical 
membrane of rabbit renal papillary surface epithelium (Sands et al” 
1986) to 8.7^M in Ehrlich ascites cells (Hoffman et al., 1986). The 
concentration for full inhibition ranges from InM in rabbit renal 
epithelium (Sands et al.，1986) to over lOO^ iM in Shark rectal gland 
epithelium (Palfrey et al., 1984). Thus, the results may indicate low 
affinity bumetanide binding sites. Bumetanide is a more specific 
inhibitor than fiirosemide as Walz and Kimelberg showed that uptake of 
42k+ was unaffected by ImM fiirosemide. However, other studies have 
shown that at concentrations of over lOO^M，bumetanide partially 
inhibits other transport pathways including anion exchange (Gurni, 
1985) and KCl cotransport (Kaji, 1986) in human red cells. Therefore, 
the inhibition may not be specific as a high concentration of 
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Effect of natriuretic peptides • 
Although the results indicate a role of astrocytes in K+ 
homeostasis, it is unlikely to involve regulation by natriuretic peptides. 
pBNP is shown not to alter the time course of Rb uptake. The uptake is 
also unaffected by various concentrations of pBNP and CNP. In 
addition，other natriuretic peptides and a cGMP analogue are without 
effect. Finally, the response of astrocytes to increasing extracellular K+ 
is not affected by CNP treatment. 
These results are in agreement with those of Beaumont and Tan 
(1990) who also found no effect of natriuretic peptides on ouabain-
sensitive Rb+ uptake in cultured rat astrocytes. Also, Hemado et al. 
(1985) have reported that synthetic ANP does not affect the ouabain-
sensitive and bumetanide-sensitive Rb+ uptake in human erythrocytes. 
It remains possible that natriuretic peptides exert an effect on the 
bumetanide-sensitive component uptake which is difficult to detect due 
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9J. Taurine Release 
92.1 Introduction 
Astrocytes clearly play an active role in controlling fht internal 
mileau of the brain under both normal and adverse conditions. They 
directly contribute to regulation of the brain extracellular environment, 
and also interact with both vascular cells and neurones. Their ftinctions 
include homeostatic mechanisms for the maintenance of balanced 
metabolic rates, maintenance of ion concentrations such as K+ and for 
the inactivation of various neuroactive substances. 
One substance that may participate in these events is the sulfiir-
containing amino acid, taurine (2-aminoethane sulfonic acid). Taurine 
has long been known to be essential for normal brain development. It 
possesses inhibitory, neuromodulatory, Ca2+ modulatory, and 
anticonvulsant properties, and may act as an osmoregulator in the CNS 
(Huxtable, 1989). 
CNS taurine arises primarily from dietary sources and hepatic 
biosynthesis. The inherent synthetic capacity for this amino acid within 
the brain is low. Biochemical and immunohistochemical evidence 
shows that taurine and its synthetic enzymes are unevenly distributed in 
the brain. At physiological pH, taurine exists as a zwitterion and its 
strongly acidic sulfonate group renders the molecule lipophobic and 
impermeable to plasma membranes (Huxtable, 1989). It is relatively 
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Cultured astrocytes release taurine and, to a lesser extent, other ' 
amino acids in response to elevated extracellular K+ (Philibert et al., 
1988). Pasantes-Morales and Schousboe (1989) speculated that, under 
these conditions, taurine, being the more abundant intracellular amino 
acid, acts as the major osmoeffector in regulating cellular volume 
decrease. In another study, they also found that taurine was released in 
response to hypoosmolarity with a time course related to the cell's 
volume regulatory phase (Pasantes-Morales and Schousboe, 1988). In 
addition, other substances such as glutamate (Kimelberg et al., 1989), 
adenosine (Madelian et al” 1988)，6-adrenergic agonists and (Madelian 
et aL, 1985) can produce astrocyte swelling and taurine efflux. 
Although more than one mechanism is apparently involved in taurine 
release, all may be related to osmolarity changes. The evidence 
suggests that taurine release from astrocytes is intimately related to cell 
volume regulation in CNS. 
Since natriuretic peptides may also be involved in cell volume 
regulation, the author attempted to investigate a possible interaction 
between natriuretic peptides and taurine release in astrocytes. 
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9二 Materials and Method 
9«2«2J Materials 
Astrocyte cultures were prepared as described previously. 
Natriuretic peptides were purchased from the sources mentioned earlier. 
Angiotensin II was from Sigma (USA) and [3H]taurine (specific 
activity of 117mCi/mg) was purchased from Amersham International 
(UK). 
9«2丄a Method 
Reagents - reaction buffer (lOmM HEPES buffer) 
-peptides diluted to lyiM concentration 




a. Astrocyte monolayers were washed twice with 1 ml reaction buffer 
b. They were then equilibrated in 1 ml buffer for 1 hr at 22�C 
c. The cells were then preloaded with [^ Hj-taurine at a concentration 
of 1 ^ Ci/ml in reaction buffer 
d. At the end of 1 hour, the solution was aspirated and the cells were 
washed twice with buffer to remove free [^ HJ-taurine 
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f. The buffer was then collected by pipette and counted for -
radioactivity 
g. The cells were washed and incubated with fresh buffer for another 
6 mins and this step was repeated 5 more times to achieve a steady 
release pattern 
h. The cells were then challenged with ANP (SOOnM) or Agll (500nM) 
i. The peptide solution was collected every 5 mins and replenished 
with identical medium for 15 mins 
j. At the end of the incubation, the cells were washed with buffer to 
remove free peptides 
k. The cells were then incubated further with 1 ml buffer and tbe 
medium was collected and replenished every 5 mins for a further 20 
mins 
1. Finally the cells were washed twice with 1 ml ice-cold PBS 
m. 1 ml 0.5N NaOH was added to each dish 
n. After 4 hours, 500pil of the neutralized NaOH lysate was taken to 
determine the amount of radioactivity and another 200^1 for protein 
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923 Results « 
A steady release pattern of [3H]taurme is established after 3 to 4 
successive washes with buffer (Fig. 92.1). The release pattern is similar 
to mouse cerebellar slices (Kontro and Oja, 1989). Addition of 500nM 
a-hANP or lOOnM Agll does not affect the rate of release during the 15 
minutes incubation time. A small stimulatory effect is observed when 
astrocytes are treated with of pBNP (Fig. 9.2.2). However, pBNP 
has no effect on taurine efflux at lower concentrations (InM to 1|jM). 
Figure 9.2.3 shows that BNP and angiotensin II (Agll) does not cause 
any significant change in taurine release although isoproterenol (IjiM) 
stimulates taurine release at a statistically significant level. This 
receptor mediated release is likely to be mediated by cAMP as 
isoproterenol is a potent B-adrenergic agonist which causes a brisk 
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92A Discussion 
The results are essentially negative, suggesting that a-hANP 
and pBNP do not affect taurine release in mouse astrocytes. Although a 
slight stimulation is seen with pBNP, this effect is unlikely to have 
physiological significance. Thus, it can be concluded that taurine 
release is not influenced by natriuretic peptides under the experimental 
conditions used. Although rodent ANP has not been tested, in results 
presented earler in this thesis make it unlikely that a species difference 
exists since rat ANP has similar binding and second messenger 
generating capability to pBNP and a-hANP, and is, if anything, less 
potent in these respects. 
It is, however, possible that natriuretic peptides exert their effect 
on taurine release stimulated by other substances. For example, taurine 
release has been shown to correlate with the mobilization of 
intracellular Ca2+ in rat astrocytes (Enkvist et al.，1989). ANP, on the 
other hand, decreases the resting intracellular Ca2+ but has no effect on 
the increase in Ca2+ induced by serum in mesangial cells (Johnson et 
al., 1988). However, it has yet to be established that natriuretic peptides 
lower astrocytic intracellular Ca2+. In addition to Ca2+，stimulation of 
taurine release by elevated K+ is well known. Natriuretic peptides are 
unlikely to influence this release as they have no apparent effect on K+ 
transport systems (see section 9.1, p. 113). 
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9 3 Thymidine Incorporation 
9丄1 Introduction 
Most research relating to natriuretic peptides has examined the 
importance of these peptides in the physiology and pathophysiology of 
salt and water homeostasis. However, there is increasing evidence that 
natriuretic peptides, in addition to their natriuretic and vasorelexant 
properties, also have growth-inhibitory activity. ANP has been shown 
to inhibit mesangial cell mitogenesis (Appel, 1988，Johnson et al., 
1988) and platelet-derived growth factor induced proliferation of rat 
vascular smooth muscle cells (Abell et al., 1989). These actions of ANP 
may be related to the widespread distribution of receptors in tissues not 
directly involved in volume regulation. Several functions of ANP in the 
CNS have been suggested, including a role as a neurotransmitter (Wong 
et al” 1986). In addition, ANP secretion by neurons in the diencephalon 
has been demonstrated (Levin et al” 1990). Astroglia, as well as 
neurons, are target cells for natriuretic peptides, expressing both 
guanylate cyclase-linked and cyclase free receptors. Thus natriuretic 
peptides could play a role in neuronal-glial signalling and this may 
include modulation of glial growth. 
In normal CNS, astroglial proliferation is typically observed 
following brain injury (Bignami and dahl, 1976; Malhotra et al” 1989). 
Astrocytes proliferating in response to injuries are termed reactive 
astrocytes. They are rich in GFAP and are larger in size. Hypertrophied 
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cytoplasmic processes. In addition, there are a number of factors that 
can stimulate proliferation of astrocytes in culture. These include 
epidermal growth factor (Leutz and Schachoer, 1981)，platelet-derived 
growth factor (Ek et al., 1982) and interleukin-l (Giulian et al., 1988). 
They have been shown to increase both thymidine incorporation and 
cell number. Natriuretic peptides have been shown to inhibit rat 
astroglial growth (Levin and Frank, 1991) as assessed by DNA 
synthesis and cell number. The mechanisms involved in all of these 
actions are poorly understood. 
Antimitogenic activity, and the underlying mechanism has 
therefore been examined in cultured mouse astrocytes using 
[3H]thymidme 
incorporation as an index of DNA synthesis. The effect 
of various natriuretic peptides and cGMP analogue have been studied. 
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93JZ. Materials and Method 
922.1 Chemicals 
Monolayer mouse astrocytes were cultured according to the 
methods described earlier. [3H]-thymidiiie (specific activity of 
117mCi/mg) was from Amersham International (U.K.). LY83583 (6-
anilino-5,8-qumolinedione) was obtained from Eli Lilly Inc (USA). All 
other chemicals were purchased from sources previously described. 
93.2.2 Methods 
Reagents - serum-free MEM 
-natriuretic peptides diluted with serum-free MEM 
-[3H]thymidme (at a concentration of l^Ci/ml) in 
serum-free MEM 
-ice-cold isotonic PBS pH 7.4 
-TCA (6% w/v) 
-NaOH (0.5N) 
Procedure 
a. Astrocytes were washed twice with serum-free MEM 
b. The cells were preincubated in this medium for 24 hours 
c. The medium was then aspirated and 1ml of different concentrations 
of natriuretic peptide or cGMP analogues was added. In order to 
study the effect of serum, natriuretic peptides in 5% serum 
supplemented MEM was added. 
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hours. . 
e. At the end of 2 hours, l^ iCi [3H]thymidme was added to each dish 
and it was further incubated for 1 hour 
f. The cells were then washed with PBS to remove any free 
[3n]thymidine 
g. 1ml TCA was then added to each dish 
h. The TCA was aspirated after 24 hours precipitation at 4�C 
i. The acid precipitate was rinsed twice with 1ml ether/alcohol 
solution to remove any remaining TCA 
j. The acid precipitate was then solubilized with NaOH 
k. The lysate was divided into 2 fractions，one to determine the amount 
of radioactivity, the other to determine the protein content. 
1. Thymidine incorporation was expressed as the percentage amount of 
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933 Result • 
As shown in figures 9.3.1 and 9.3.2, a-hANP and pBNP inhibit 
[3H]thymidine incorporation into mouse astrocytes in a similar 
concentration dependent manner. The half maximal inhibitory 
concentrations are approximately 0.5nM for pBNP and InM for a -
hANP. At the maximal inhibitory concentration, pBNP inhibits 40% of 
[3H]thymidme incorporation while hANP induces a 30% inhibition. 5% 
horse serum induces a 25% increase in [^H]thymidine incorporation in 
mouse astrocytes (Fig. 9.3.3). This stimulatory effect of horse serum is 
abolished by the addition of hANP or pBNP (Fig. 9.3.3). 
Figure 9.3.4 shows the effect of various natriuretic peptides， 
including a ring-deleted analogue of ANP (C-ANP(4_23)) which does 
not stimulate cGMP production in mouse astrocytes (unpublished 
observation), a truncated rat ANP (rANP(5_28)) and the C-type 
natriuretic peptide (CNP) which is more potent than ANP or BNP in 
stimulating cGMP production in mouse astrocytes (see section 5.5, p. 
22 )，and a cGMP analogue (dbcGMP), on [^H]thymidine incorporation 
in mouse astrocytes. It can be seen that all inhibit [3H]thymidine 
incorporation to a similar extent (25-35%). When astrocytes are treated 
with different concentrations of dbcGMP, [3H]thymidme incorporation 
is inhibited in a concentration dependent manner although the 
concentration for maximal inhibition (lOOmM) is much higher than 
those of the natriuretic peptides. 
Table 9.3.1 depicts the effect of LY83583 (6-anilino-5,8-
quinolinedione) on natriuretic peptide-stimulated cGMP production and 
inhibition of [3H]thymidme incorporation. LY83583 significantly 
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blocks cGMP production induced by pBNP and CNP at their half . 
maximal stimulatory concentrations. pBNP and CNP, however, still 
exert an inhibitory effect on [3H]thymidme incoiporation despite the 
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Table 9.3.1 • 
Effect of LY83583 (lOmM) on pBNP- and CNP-stimulated cGMP 
production, pBNP- and CNP-inhibited thymidine incorporation. Results are 
means 土 SEM of two separate experiments, each with triplicate 
determinations. * represents statistical significance (p <0,001) from the 
control and + indicates the values are statistical significant (p <0.001) from 
the group not treated with LY83583. 
cGMP production Thymidine incorporation 
(pmol/mg protein) (cpm/mg protein) 
Control 3.18 ± 0.1 18347 土 1763 
pBNP (lOOnM) 7.78 ±1.09* 11568 ±1745* 
CNP (lOOnM) 6.39 土 0.70* 13472 土 1607"^  
pBNP + LY83583 4.47 土 0.37+ 11038 土 448+ 
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Fig. 9.3.1 Concen t ra t ion dependence of pBNP- induced 
inhib i t ion of thymid ine incorporat ion. Values are expressed 
as % of thymid ine incorporat ion to contro l 土 SEM of 4 
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Fig. 9.3.4 Effect of different natriuretic pept ides and a cGMP analogue 
on thymid ine incorporat ion in mouse astrocytes. Values are expressed 
as % of contro l (100%), where the control is [^H]thymidine 
incorporat ion with serum-free MEM alone. Results are Means + SEM 
of 2 separate experiments, each performed in tr ipl icate. 
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93.4 Discussion 
These results demonstrate that natriuretic peptides are able to 
inhibit growth as assessed by [3H]thymidme incorporation in mouse 
astrocytes. The half maximal inhibitory concentrations for BNP and 
ANP are approximately O.lnM which is close to the IC50 obtained 
previously with competitive displacement receptor binding experiments 
(see section 7，p.59). This antiproliferative action of natriuretic peptides 
appears not to be mediated by cGMP. In the experiments characterising 
cGMP response in astrocytes, the half maximal concentration (EC50) of 
BNP and ANP for cGMP stimulation is approximately lOOnM (see 
section 8，p. 97). However, the present study indicates that natriuretic 
peptides can inhibit diymidine incorporation at much lower 
concentrations (0.1-InM). This is further supported by the finding that 
CANP(4.23) is equipotent to hANP and pBNP in inhibiting thymidine 
incorporation despite evidence that CANP(4-23) only binds to the non-
guanylate cyclase linked ANP-C receptors and does not generate 
cGMP. Also, C-lype natriuretic peptide (CNP), which is more potent in 
stimulating cGMP production in mouse astrocytes (Yeung et al, 1992), 
shows similar potency to ANP and BNP in inhibiting thymidine 
incorporation. Finally, the addition of LY83583 (6-anilmo-5,8-
qumolinedione), a compound which can inhibit the production of 
cGMP (Schmidt et al.，1985)，did not abolish the inhibitory effect of 
BNP and CNP on thymidine incorporation, indicating a separate 
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Thus，although the precise mechanism of this effect is not • 
known，it appears to involve the ANP-C receptor rather than tibe 
guanylate cyclase linked receptors. The fact that C-ANP is able to 
inhibit thymidine incorporation with similar potency to ANP and BNP 
provides direct evidence for this, since C-ANP is a synthetic ring-
deleted analogue which selectively binds to the ANP-C receptor and 
does not stimulate cGMP production. This is further supported by the 
finding that CNP，which is more potent in stimulating cGMP 
production, is also equipotent to ANP and BNP. 
This raises the question as to which second messenger systems 
mediate this response. Several studies now suggest that the ANP-C 
receptor may inhibit adenylate cyclase activity (Anand-Srivastava et al” 
1986) and induce an activation of phosphatidylinositol breakdown 
causing an increase in inositol phosphates (Resind et al.，1988; Hirata et 
al., 1988). However, cAMP has been found to inhibit proliferation in 
cultured glioma cells (Davies and Vemadakis, 1986). Thus, inhibition 
of cAMP production should, if anything, increase proliferation rather 
than decrease it. Also, previous results (see results on second 
messengers on p.97) indicate that ANP does not affect basal cAMP 
level although it may inhibit forskolin-stimulated cAMP production at 
low concentrations. Therefore，it is unlikely that natriuretic peptides 
inhibit thymidine incorporation by inhibiting adenylate cyclase. 
Another possible candidate is Ca2+. In this connection, ANP has 
been shown to decrease basal and hormone-stimulated cytosolic Ca2+ 
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in cultured mesangial cells (Appel et al, 1987; Hassid, 1987; Johnson et 
al.，1988). This effect would be predicted to be antimitogenic as an 
increase in cytosolic Ca2+，typically seen following the action of 
growth factors (Moolenaar et al., 1984), will usually lead to protein 
kinase C activation and a proliferative response. 
The inhibitory effect of natriuretic peptides appears to be 
independent of the proliferative action of horse serum. Their effects 
cancel each other out and thymidine incorporation returns to control 
values. 
It remains uncertain whether this in vitro effect is relevant to 
normal physiology and pathophysiology. The fact that natriuretic 
peptides can inhibit proliferation in vascular tissues may be relevant in 
such conditions as atherosclerosis, vascular internal proliferation and 
cardiac hypertrophy. In astrocytes, the situation is even less clear as no 
other action of natriuretic peptides has yet been identified. It may also 
be of importance to counteract the mitogenic effects of other vasoactive 
peptides also found in the brain, such as endothelin (Supattapone et al.， 
1989) which has been shown to increase cytosolic Ca2+ and promote 
thymidine incorporation in astrocytes. In addition, natriuretic peptides 
may have a role in regulating reactive gliosis and brain development. In 
the presence of dbcAMP, astrocytes appear to assume morphologies 
similar those found in the vicinity of a wound (i.e. reactive astrocytes). 
Since the astrocytes used in the present experiments were cultured with 
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found in vivo. Therefore, if natriuretic peptides can inhibit proliferation 
in these cells, it may be that they behave similarly in vivo, A role of 
natriuretic peptides in brain development is supported by the finding of 
ANP production by neurons, full receptor expression in glia, major 
changes in ANP binding in various areas of the CNS during maturation 
(Tong and Pelletier, 1990), and suppression by ANP of basal and 
hormone-stiniulated secretion of growth hormone from the anterior 
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10. Effect of Angiotensin H on the interaction between 
natriuretic peptides and mouse astrocytes 
10.1 Introduction 
Angiotensin II (Agll) and natriuretic peptides are fimctionally 
antagonistic hormones involved in blood pressure and body fluid 
regulation. Agll has sodium and water conserving actions by direct 
effect on the kidney as well as stimulation of aldosterone release from 
the adrenal gland and vasopressin release from the pituitary. It also 
increases blood pressure by inducing vasoconstriction (Vallotton, 
1986). Natriuretic peptides, on the other hand, oppose these effects of 
Agll and cause diuresis and natriuresis and vasorelexation (DeBold, 
1985). 
The effects of Agll and natriuretic peptides were first described 
and studied in relation to their effects in the periphery. However, they 
have also been found in the CNS where they may function as 
neuropeptides. Agll receptor has been identified in the suprachiasmatic 
and periventricular areas such as the subfornical organ (SFO), 
anteroventral-third ventricle (AV3V) and the organum vasculosum 
laminae terminalis (OVLT) (Saavedra et al” 1986; Shigematsu et al., 
1986). ANP binding sites have also been shown in close vicinity 
(Quirion et al., 1986). Centrally administered ANP and BNP have been 
shown to inhibit the dipsogenic action, central pressor responses and 
vasopressin release induced by Agll (Nakamura et al., 1985; Casto et 
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potentiates Agll-mduced drinking (Samson, 1987). In addition, the • 
number of binding sites of Agll in several animal models of congenital 
and mineralocorticoid-salt induced hypertension are substantially 
increased whereas those of ANP are greatly reduced in similar brain 
areas (Saavedra, 1990). Thus, these peptides are intimately associated 
and their interaction in the CNS may be as important as in peripheral 
tissues in maintaining fluid and blood pressure homeostasis. 
Most of these studies are concerned with the effect of ANP or 
other natriuretic peptides on Agll-induced actions in intact CNS. Given 
that astrocytes possess functional receptors for natriuretic peptides, 
experiments have been performed to investigate the effect of Agll on 
natriuretic peptide binding and cGMP production in response to 
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10«2 Materials and Method 
10丄1 Materials 
Mouse astrocytes were cultured as described previously. 
Angiotensin U was purchased from Sigma Co. (USA). All other 
chemicals were obtained as previously mentioned. 
10.2.2 Methods 
Effect of Agll onl25i,ANP binding to mouse astrocytes 
The methodology for this experiment is essentially the same as that 
described earlier in relation to competition binding experiments. In the 
test group, unlabeled natriuretic peptides were replaced with different 
concentrations of Agll. The amount of ^^^I-hANP bound to astrocytes 
and protein content were determined according to the method 
previously described. 
I 
Effect of Agll on natriuretic pep tide-induced cGMP production in 
mouse astrocytes 
The effect of Agll on cGMP production induced by natriuretic 
peptides has been investigated by adding Agll into the reaction medium 
with natriuretic peptides and then determining the concentrations of 
cGMP produced. cGMP measurement was based the principle of 
radioimmunoassay. A commercial kit was employed for this purpose. 
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103 Results -
As shown in figure 10.1，Agll in itself does not influence the 
binding of ^^ l^-hANP while a-hANP at a concentration of 0.14nM 
effectively displaced 50% of 125i-hANP binding (Fig 10.1). Agll, over 
concentrations ranging from lOnM to l^M, has no effect on the basal 
cGMP production in mouse astrocytes (Fig. 10.2), nor does it affect 
cGMP production stimulated by hANP or pBNP when they are added 
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Fig. 10.1 Displacement of ^^sj.hANP by hANP and Agll in 
mouse astrocytes. Results are means of a representative 
experiment. 
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•一 • 10.4 Discussion 
The results indicate that Agll does not appear to interact with the 
binding of natriuretic peptides to their receptors in cortical astrocytes 
and has no interaction with the guanylate cyclase system. However, 
these are acute experiments and the possibility of long term regulation 
of natriuretic peptide receptors by Agll cannot be ruled out In vascular 
smooth muscle cells, Agll diminishes the number of ANP binding sites 
in a concentration- and time dependent manner (Saavedra, 1990). This 
effect is abolished by the addition of a specific Agll receptor 
antagonist, Sari-Ileg-Agll. These findings suggest a unique and tight 
coupling between the two peptide hormone receptor systems even if 
this effect is not reciprocal In addition, 18 hours incubation with Agll 
has been shown in vascular smooth muscle cells to potentiate the 
guanylate cyclase system despite the reduction in total receptor number. 
Thus，although Agll does not have acute effects on natriuretic peptide 
action in astrocytes. Experiments with long term exposure of astrocytes 
to Agll are required to evaluate the possibility of more chronic effects. 
The opposition interaction, i.e. ANP affecting Agll receptor and 
function, is also possible. Recently, specific high affinity binding sites 
for Agll have been identified in primary cultures of glial cells from the 
hypothalamus, brain stem (Raizada et al.，1987), and spinal cord 
(Simonnet et al.，1988), and in rat C6 glioma cells (Prmtz et al., 1986). 
Functionally, Agll stimulates the hydrolysis of phosphoinositides in 
primary cultures of rat glial cells (Raizada et al., 1987) and causes 
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release of prostaglandin E2 and prostacyclin (PGIzi from human 
(Katsmira et al” 1989) and rat astrocytes (Wroblewska et al., 1988) and 
rat glioma cells (Jaiswal et al., 1991). Natriuretic peptides may have an 
effect on one or more of these actions ofAgIL However, specific Agll 
binding sites in mouse cortical astrocytes have not been identified, and 
fiirther studies have not been performed. 
The lack of effect of Agll on ANP actions in cortical astrocytes is 
of interest since these cells are as highly responsive to ANP as 
astrocytes from other brain regions (unpublished observation from our 
group). However, interactions between Agll and ANP in astrocytes 
from other brain regions remain possible if the Agll response shows 
regional selectivity within the CNS. 
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•一 11. Conclusion 
‘ 
The binding and competitive binding experiments show that 
specific receptors for natriuretic peptides are present in mouse 
astrocytes. These binding data, following Scatchard transformation, 
reveal a single class of high affinity receptor with a dissociation 
constant (Kd) o f 0.2-0.3nM and maximal binding (Bmax) between 42 
to 90 fmoVmg protein. This binding characterisitcs is consistent with 
other studies with rat astrocytes (with Kj ranging from 0.11 to 0.17 nM 
and Bmax from 78.1 to 125 fmol/mg) and comparable to those in 
adrenal cortex (with a Kd of 0.23nM and Bmax of 40 fmol/mg) • It is 
likely that this receptor is shared by ANP and pBNP. The similarity of 
self- and cross-displacement of various radiolabeled ligands by 
unlabelled ligands, with IC50 values ranging from 0.1 to 0.4nM， 
strongly support this hypothesis. 
Binding to this receptor can activate guanylate cyclase and lead 
to cGMP production. The half maximal stimulatory concentrations 
(EC50) are similar (approximately lOOnM) although the maximal 
response of pBNP is greater than ANP. When both peptides are studied 
together, no additive or synergistic effect can be observed. This further 
support the proposition that they bind to a common receptor and 
employ the S2[me effector system to generate cGMP. 
In terms of cAMP production, natriuretic peptides appeared not 
to affect basal cAMP production although they can inhibit cAMP 
production in response to low, although not high, concentrations of 
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In the series of experiments conducted to identify the biological 
actions of natriuretic peptides in astrocytes, varying results are found. 
Natriuretic peptides have been shown to inhibit thymidine 
incorporation. a-hANP and pBNP inhibit thymidine incorporation in a 
similar concentration dependent manner with a half maximal inhibitory 
concentration of approximately O.lnM. This value is close to the IC50 
and Kd values derived from the binding experiments, indicating that 
natriuretic peptides at physiological concentrations may inhibit 
astrocyte proliferation. It is unlikely that cGMP is involved in the 
mediation of this response as CANP(4.23), which does not stimulate 
cGMP production, and CNP, which is more potent than pBNP and a-
hANP，are equipotent in inhibiting thymidine incoiporation. These 
results are consistent with the findings that the EC50 values for 
natriuretic peptide-induced cGMP generation are lOOnM and at 
concentrations between O.l-lnM they do not stimulate cGMP 
production to any significant extent. These results are similar to other 
studies with rat astrocytes. This antiproliferative response may have 
implications in such conditions as reactive gliosis or astroglial 
proliferation induced by other vasoactive peptides present in the CNS. 
As far as potassium transport is concerned, mouse astrocytes 
have a very rapid K+ uptake (with an initial uptake rate of 170-
200nmol K+mg-lmiirl)，measured as Rb+ uptake. The Na-K-Cl 
cotransport account for only a small percentage (less than 10%) of the 
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total uptake, whereas the Na+-K+ pump contributes 30-40 percent. This 
is in marked contrast to rat astrocyte (uptake rate of 19.6nmol K+mg-
lmiirl)but in agreement with other published reports in mouse 
astrocytes. The majority of K+ transport occurs by passive K+-
channels. Uptake by these channels increases when extracellular K+ is 
increased, unlike the Na+-K+ pump and Na-K-Cl cotransport system. 
These transport systems do not appear to respond to natriuretic 
peptides. Also, natriuretic peptides have no effect on taurine release in 
mouse astrocytes. 
Other 
vasoactive peptides, such as angiotensin II，neither 
influence the binding of natriuretic peptides nor cGMP production in 
response to them. 
Finally, culture conditions have a marked effect on the interaction 
between astrocytes and natriuretic peptides. Astrocytes grown without 
dbcAMP have a decreased cGMP response. Acute treatment of 
forskolin in these cells result in an increase in binding sites for 
natriuretic peptides in these cells indicating that the natriuretic peptide 
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13. Appendix I 
List of Abbreviation 
Agll Angiotensin II 
ANP Atrial Natriuretic Peptide 
hANP Human ANP 
rANP Rat ANP 
cAMP Cyclic Adenosine Monophosphate 
DbcAMP Dibutyl cAMP 
Bmax Maximal Binding Capacity 
BNP Brain Natriuretic Peptide 
hBNP Human BNP 
pBNP Porcine BNP 
- BSA Bovine Serum Albumin 
CNP C-Type Natriuretic Peptide 
EC50 Half Maximal Excitory Concentration 
GFAP Glial Fibrillary Acidic Protein 
cGMP Cyclic Guanosine Monophosphate Br-cGMP Bromo-cGMP 
GS Glutamine Synthetase 
HEPES (N-[2-Hydroxyethyl]Piperazine-N'-[2-Ethane 
Sulfonic Acid]) 
IBMX 3-Isobutyl-1 -methylxanthine 
IC50 Half Maximal Inhibitory Concentration 
Kd Dissociation Constant 
LY83583 6-aiiilino-5,8-quinolinedione 
MEM Minimal Essential Medium 
Na+-K+ ATPase- Sodium Potassium Adenosine Triphosphatase 
PBS Phosphate Buffered Saline 
RIA Radioimmunoassay 
TCA Trichloroacetic Acid 
‘VIP Vasoactive Intestinal Peptide 
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Attached is copy of a published report in relation to this M.Phil, 
study entitled: "Interaction of natriuretic peptides and cGMP 
production via the same receptor in mouse astrocytes." 
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I Interaction of natriuretic peptides and cGMP production • 
via the same receptor in mouse astrocytes 
C.W.K. Ngai a，S.L.N. Ng � C S . Cockram % CM. Lee 卜，V.T.F. Yeung ^ and M.G. Nicholls� 
Departments of " Medicine and ‘ Biochemistry, Chinese University of Hong Kong, Shatin, N.T., (Hong Kong) and ^ Department of Medicine 
The Chnstchurch School of Medicine, University of Otago, Cliristchurch (New Zealand) ’ 
(Accepted 31 March 1992) 
Key words: Cyclic guanosine 5-monophosphate; Natriuretic peptide; Natriuretic peptide receptor; Astrocyte; Brain 
Atrial and brain natriuretic peptides have been found previously to bind to specific receptors on cultured mouse astrocytes and to stimulate cyclic 
guanosine 5-monophosphate (cGMP) production with similar dose dependency although brain natriuretic peptide (BNP) shows a greater 
maximal stimulatory effect. The present study provides evidence that both peptides work through the same pathway. No additive or synergistic 
effect was observed when astrocytes were exposed to both peptides. However, human ANF(99-126) at high concentrations partially inhibited 
porcine BNP induced cGMP production to the level seen with ANF alone. ANF could be viewed as a partial agonist of pBNP competing for the 
same effector sites. Differences in structure between human ANF(99-126) and porcine BNP may account for the difference in cGMP response. 
The interaction between the two peptides and the cGMP response does not reflect receptor binding affinities and is likely to be a post-binding 
event. 
INTRODUCTION the two peptides. Futhermore, in competitive binding 
experiments similar potencies in displacing each other 
Atrial natriuretic peptide was first isolated from from the receptors were demonstrated with an IC50 in 
mammalian atria and has been purified, sequenced and the nanomolar range。，. These data suggest that BNP 
characterised*. It has potent physiological effects in- and ANF interact with the same binding sites. How-
cluding diuresis and natriuresis, inhibition of aldos- ever, discrepancies exist between the two peptides con-
terone secretion by the adrenal cortex, inhibition of cerning the magnitude of cGMP response with BNP 
angiotensin Il-induced dipsogenic effects and relax- exerting a greater maximal stimulatory effect on cGMP 
ation of vascular smooth muscle Specific ANF re- production. In addition, approximately 100-fold higher 
ceptors have been identified in both neurons" and concentrations of both peptides are required for cGMP 
astrocytes2，5，2o. Binding of ANF to these receptors leads generation (as indicated by an EC50 of about 100 nM) 
to the generation of intracellular cyclic guanosine 5- as compared to their binding potency. In light of these 
1 monophosphate (cGMP)5，i2,i3 findings, we proceed to explore further the interaction 
In 1988，a closely related peptide, brain natriuretic between ANF and BNP on cGMP generation in cul-
peptide (BNP), was isolated from porcine brain^^ It tured mouse astrocytes, 
has been shown to produce similar physiological ef-
fectsio’i9 and to share close sequence homology to MATERIALS AND METHODS 
ANF 6. It has been reported to interact with the ANF 
receptor in cultured vascular muscle cells^. We have Materials 
previously shown that both A N F and B N P bind to Human ANF(99-126) and porcine BNP (pBNP) were purchased 
cultured mouse astrocytes. Binding of these peptides Bachem (Switzerland) and Peninsula Laboratory (USA), re. • . , , , , , „ , , spectively. 3-Isobutyl-l-methylxanthine (IBMX), dibutyryl cyclic was concentration dependent and saturable. Scatchard AMP, H E P E S and bovine serum albumin were obtained from Sigma 
analysis revealed similar receptor binding affinities for (USA). Horse serum, amino acids and antibiotics were purchased 
Correspondence: C.W.K Ngai, Department of Medicine, Chinese University of Hong Kong, Shatin, N.T., Hong Kong. 
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from Gibco Laboratories (USA). The culture dishes were from TABLE I 
Falcon Labware (USA). The cGMP radioimmunoassay kit was from . . . , Amersham International (UK) cGMP production in mouse astrocytes in response to maximal stimula-tory concentration of human ANF(99-126) (1 fiM) alone and in the presence of 1 jxMporcine BNP 
^^^^ods Data are expressed as means 士 S.E.M. of at least 5 separate experi-
1- Culture of astrocytes. Primary cultures of mouse astrocytes were ments. 
prepared according to the method of Hertz et al7 with some modifi-
cations (Kum et al.iia). Peptide cGMP roduced 
In brief, the subependymal germinal plates from the lateral ( . ^ . , 
ventricles of brains from 1- to 2-day-old mice were dissected using an / mg pro em 
aseptic technique. The cell suspensions were distributed at a plating Control 1.95±0.14 
density of 1x10^ cells/cm^ into 35-mm-diameter culture dishes A N F ( l / i M ) 4.07 士 0.40 
containing Minimal Essential Medium (MEM) with a double concen- BNP (1 iiM) 10.32士 1.02 
tration of all amino acids except L-glutamine (2.8 mM), a quadmple ANF(1 MM)-I-BNP(1 /XM) 6.58 ±0.55 
concentration of MEM vitamin solution, 20% horse serum, 200 ‘ 
l U / m l of penicillin, and 200 /xg/ml of streptomycin. Modification of 
astrocytes into the process-bearing form was induced at confluence 
(on day 12-14 of culture) by addition of 0.25 mM dibutyryl cyclic 
adenosine 3'5'-monophosphate (AMP) in MEM supplemented with 内 — m n . DXTT I T R 
10% horse serum. Binding and biological studies were carried out 2 Presence of 100 nM porcine BNP. In the absence of 
weeks after confluence. Regular monitoring with indirect im- pBNP, cGMP increased from a basal value of 0.79 
munofluorescence using anti-glial fibrillary acidic protein antiserum p m o l / m g protein to 19.8 p m o l / m g protein with in-
showed that ~ 95% of the cells were glial fibrillary acidic protein . - , . « . . . _ . _ 
positive. creasing concentrations of human ANF (1-10 /iM). It 
2. Measurement of cellular cGMP accumulation. Mouse astrocytes can be seen from Fig. 1 that with 100 nM pBNP alone, attached to 35-mm-diameter tissue culture dishes were washed twice the cGMP production reached was 27.1 p m o l / m g pro-with binding buffer (10 mM HEPES and 1% BSA in MEM) and then . , . , , � . . r . , preincubated for approximately 10 min with 1 ml of binding buffer tem which Showed no Significant difference from the supplemented with the phosphodiesterase inhibitor IBMX at 1 mM value given by a low concentration of human A N F 
(final concentration). No significant difference in cGMP production together with 100 nM pBNP. Further increase in the was observed when the cells were preincubated between 3 to 10 mm . . . . 
with IBMX (data not shown) before incubation with the peptides. concentration of h A N F caused a significant reduction 
Following preincubation, human ANF and porcine BNP were added of cGMP production. The two curves met at hANF 
to the cells simultaneously in the presence of IBMX, and incubation _ i i \/f -ru^ i ‘ � • -c- ^ J f in . 〜广-ru • u • . ^ , , concentration or 3.3 uM. ihe results shown in Fig. 1 continued for 10 mm at 22°C. The incubation was terminated by ^ ® aspirating the solution and rinsing the cells with 1 ml ice-cold were from separate experiments to those shown in phosphate-buffered saline twice. Intracellular cGMP was released by Table I. Although the magnitudes of the total cGMP 
adding 1 ml of 6% (wt./vol.) ice cold trichloroacetic acid. After ^ . freezing at - 20�C for 2 h, the cell residues were scraped off, and the response varies in different experiments, the interac-
suspension was transferred to test tubes for centrifugation at 2,000 X g 
for 20 min. The supernatant was extracted 4 times with 2 ml of 
water-saturated diethyl ether to remove trichloroacetic acid. The 
aqueous layer was then lyophilized and reconstituted in cGMP assay 
buffer in 0 � C ice bath (50 mM Tris-HCl and 4 mM EDTA, pH 7.5). 
Following acetylation (Brooker et al.^), cGMP in the sample was . _ _ , hANF alone measured by radioimmunoassay. T h e pellet was lysed with 1 ml 0.5 丁 o _ _ � with lOOnM pBNP 
M NaOH, and the protein concentration determined using the 
method of Lowry et al.^ ^®. 
t RESULTS 3 30- ^ I r 1 
The effects of a fixed concentration of porcine BNP | 丄 � � ！ 
(100 nM) on cGMP production induced by varying 20-
concentrations of human ANF (10-9-lO— m) and of | V l t 
a fixed dose of ANF (lO— M) on pBNP (lO-'-lO"^) ^ / 
stimulated cGMP production were studied. As shown 10- V 
in Table I both human ANF and BNP were able to A 
stimulate cGMP production, the response to BNP be- " • 
* ing greater. When both peptides at maximally stimula- ° 0 ‘ ~ ^ ^ i o * ® 
tory concentration were added together, there was no peptide conc. (M) 
additive or enhanced effect and the cGMP produced in i Effect of porcine BNP on human, anf(99-126) stimulated 
response to the peptides in combination is lower than cGMP production in mouse astrocytes. The lower curve shows the 
u., OKTP ol^riA dose-rcsponse curve of human ANF alone. The upper curve is the that produced by B N P alone. dose-response of human ANF in the presence of 100 nM porcine 
Fig. 1 shows the dose -response curve for human bNF. Data are expressed as means 土 S.E.M. of 5 separate experi-




\ ； r A N F and B N P remains quan偷e ly the hypothesis that h A N P and pBNP share the same 
receptor but ANF may be viewed as a partial agonist of 
DISCUSSION BNP with regard to cGMP generation in mouse astro-cytes. 
The fact that exposure of astrocytes to a high con-
centration of ANF (1 mM) in the presence of BNP (100 REFERENCES 
nM) did not produce any additive or synergistic effect 
on c G M P production compared with 100 nM B N P ^ Baxter, J.D., Lewicki, J.A. and Gardner, D.C. Atrial natriuretic 
alone supports the hypothesis that both peptides em- 2 二 : "pIT^^—^^tria丨 a d b •‘ 
ploy the same effector system. Further, since a high uretic peptides upon c^chrGMP^^^^^^^^^^^  
concentration of ANF suppressed the pBNP induced 25?-2S rat astroytes’ J. Neurosci. Res., 25 (i990) 
i CGMP response, it is likely that the two peptides 2a Br^oker, G.，Harper, J.F., Teraseki, W.L. and Maylan RD 
！ compete tor the same effector sites. This is supported Radioimmunoassay of cyclic AMP and cyclic GMP Adu Cvciir 
I by evidence that the maximal response of BNP is about 3 ^ ： ‘ 二 ， ( ， , • 
I d二 l e that of ANF although t h e y l t h s t i m u l 二二 ^ 二 二 二 = 
s production in a similar dose-dependent fashion and "renc peptides of two different receptor guanylate cyclases, 
二 J 二 a similar E ^ of about 励 nM. In the pres- 4 二 9 : 9 ‘二L ’ h.b.，Ve….T. and s 一 e r g H 
ence of a maximal stimulatory dose of ANF, the re- 八 rapid and potent natriuretic response to imrJ:二 
i sponse of c G M P to B N P is reduced to levels similar to , f.atna丨 myocardial extract in rats, Life ScL, 28 (1981) 89-94. 
t those found in the presence of ANF alone. Thus, ^ 
either the cGMP response requires high receptor OCCU- cyclic GMP levels in astroglia-rich cultures from murine brain J. 
pancy to concentrations well above the I C � for bind- . ^eurochem 52 iim) 5%9-59i. ’ . 
the extent of guanylate cyclase ^ 二 ‘ ^ ^ ^ ^ 。 
A N F and B N P binding is different. It may also be tide; another modulator of bovine adrenocortical steroidogenesis 
� = b l e that an unrecognised low affinity receptor' 7 A^二L丨er’ N.，Mu_ s and FedcJ 
s u b t y p e IS i n v o l v e d . roff’ S, Kinetic characteristics of the glulamate uptake into nor-
The discrepancy between binding affinity and cGMP « astrocytes m culture, Neurochem. Res., 3 (1978) 1-14. 
: n ^ ： ： ： ' by the values of IC5。(0.1-1 nM) I ： ； 二 ， 二 
> ana 11^50 UUU nM) may infer that a very high receptor uretic peptide receptor in cultured rat vascular smooth muscle 
occupancy is required to elicit the cGMP second mes- 9 Hirata^T p � , 
senger system. However, other second messenger sys- “： ^： ! " ^：：；； ! ^ ^ ? ^ ^ ^ 二 二 二 
tems，as yet unrecognised, may be activated at much Jured bovine aortic smooth muscle cells, Biophys. Acta, 1010 
concentrations of agonist. It has been shown that 10 :)二。’ K., Ya_a，T.，Shirakami，a, Shirakami G 
AJNl^  induced breakdown of phosphatidylinositol phos- Kangawa K.’ Minamino, N- Matsuo, H. and Imura, H.，Ant丨dip: 
p h a t e s a n d g e n e r a t i o n o f i n o s i t o l p h o s p h a t e s in v a s c u - s c e n i c action of a novel peptide, 'brain natriuretic peptide', in 
l a 了 0 = muscle cells" takes place with a half-maxi- n ；：日^^；；^/^^：^旦日。。)!^)^!^^.幻呂。丫，！随日 h 
mally effective concentration of about 10 一 10 M. In our and Sano, Y.，Immunohistochemical demonstration of a-atrial 
previous report, r A N F and rANF5_28 also displayed ；“二二二;78°^丫『1�9口8認。二ntaining eurons in the rat brain，恥-
Similar binding affinities yet had different effects on Ha Kum, W.，Cockram, C—S.，. Zhu, S.Q., Teoh, R.，Vallance-Owen, 
‘ c G M P generation24. Since the binding site in these J. and Young, J.D. Insulin binding and effect on pyrimidine 
二e^tides is highly conserved, this may indicate that ZTf'tuZ^ ^^ ^^ ^^ ^^ ^ mouse astro-
dlfferences in the structure might modify the degree of 12 Leitman, D.C., Andresen, J.W., Catalano, R.M., Waldman, S.A., 
guanylate cyclase stimulation and they may also be 丁“抓’and Murad, R, Atrial natriuretic peptide binding: 
nart ia l a a n n k K fnr th^ car^^ � — u .‘ . cross-linking, and stimulation of cyclic GMP accumulation and partial agonists tor the same receptors. However, it is particulate guanylate cyclase activity in cultured cells J. Biol. possible that there are ANF-receptors other than the Chem., 263 (1988) 3720-3728. ’ 
66 kDa and 130 kDa receptor 22-23. Recent studies bv ^^ a Low '^, O.H., Rosebrough, N.J., Farr, A丄.and Randall, R.J., nur^r.^ of o丨3 J . , y Protein measurement with the folin phenol reagent, J. Biol Lhang et al . demonstrated a second guanylate Chem., 193 (I95i) 265-275. 
icyclase-linlced A N F receptor which is preferentially ^^  Lyall, F.，Balmforth, A.J. and Morton, JJ.，Specific binding of 
i a c t i v a t e d by p B N P T h e n r e s e n c e o f the^e recentnvK in atrial natriuretic peptide increases cyclic GMP levels in human uy p D i � r . i n c presence or tnese receptors in astrocytoma cells, J. Endocrinol., 117 (1988) 315-321 .astrocytes could contribute to the greater cGMP re- 14 Morii, N.，Nakao, K., Sugawara, A., Sakamoto, M.’ Suda, M.， 
isponse upon stimulation by pBNP. Shimokura, M.，Kiso, Y., Kihara, M.，Yamori，Y. and Imuri H.,' 
T „ , • r- , , r , Occurrence of atrial natriuretic polypeptide in brain, Biochem I In conclusion, our findings lend further support to Biophys. Res. Commun., 127 (1985) 413-419. 
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